10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)

x  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2013

or

o  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to_________

Commission File Number:  333-173039

HEALTH REVENUE ASSURANCE HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Nevada	99-0363866
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

8551 W. Sunrise Boulevard, Suite 304

Plantation, Florida 33322

(Address of principal executive offices) (Zip Code)

(954) 472-2340

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x     No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for shorter period that the registrant was required to submit and post such files). Yes  o      No  x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer              o		Accelerated Filer                               o
Non-Accelerated Filer                o	(Do not check if a smaller reporting company)	Smaller Reporting Company            x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨       No  x

There were 46,511,409 shares of the Registrant’s Common Stock outstanding at August 7, 2013.

HEALTH REVENUE ASSURANCE HOLDINGS, INC.

QUARTERLY REPORT ON FORM 10-Q

For the Period Ended June 30, 2013

TABLE OF CONTENTS

		Page
PART 1 - FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements (Unaudited)	1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23
Item 4.	Controls and Procedures	23
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	24
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3.	Defaults Upon Senior Securities	24
Item 4.	Mine Safety Disclosures	24
Item 5.	Other Information	24
Item 6.	Exhibits	24
SIGNATURES		25

CAUTIONARY STATEMENT ON FORWARD-LOOKING INFORMATION

This Quarterly Report on Form 10-Q (this “Report”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “anticipate,” “believe,” “estimate,” “intend,” “could,” “should,” “would,” “may,” “seek,” “plan,” “might,” “will,” “expect,” “predict,” “project,” “forecast,” “potential,” “continue” negatives thereof or similar expressions. Forward-looking statements speak only as of the date they are made, are based on various underlying assumptions and current expectations about the future and are not guarantees. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements.

We cannot predict all of the risks and uncertainties. Accordingly, such information should not be regarded as representations that the results or conditions described in such statements or that our objectives and plans will be achieved and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. These forward-looking statements are found at various places throughout this Report and include information concerning possible or assumed future results of our operations, including statements about potential acquisition or merger targets; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future acquisitions, future cash needs, future operations, business plans and future financial results, and any other statements that are not historical facts.

These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report.

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

CERTAIN TERMS USED IN THIS REPORT

When this report uses the words “we,” “us,” “our,” and the “Company,” they refer to Health Revenue Assurance Holdings, Inc.  “SEC” refers to the Securities and Exchange Commission.

HEALTH REVENUE ASSURANCE HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30,			December 31,
	2013			2012
	(unaudited)
Assets
Cash	$	171,183		$	893,458
Accounts receivable		1,510,690			1,246,814
Prepaid expenses		91,270			3,600
Other current assets		12,831			688
Total Current Assets		1,785,974			2,144,560
Property and Equipment, net		411,120			365,017
Software		940,305			258,933
Other assets		8,865			8,871
Finance costs, net		2,313			2,477
Total Other Assets		951,483			270,281
Total Assets	$	3,148,577		$	2,779,858
Liabilities and Stockholders' Equity
Accounts payable	$	338,296		$	207,741
Due to officer		75,000			75,000
Accrued expenses		136,152			64,077
Accrued payroll		641,621			412,186
Loan payable to factor		552,439			827,075
Accrued interest		-			4,524
Lines of credit, current portion		74,791			25,000
Capital Leases, current portion		21,972			16,923
Notes payable, current portion, net of discount		574,718			202,557
Long term debt, current portion		32,610			37,513
Settlement Payable		23,056			115,278
Total Current Liabilities		2,470,655			1,987,874
Capital Leases (net of current portion)		30,565			23,974
Line of credit (net of current portion)		111,637			125,000
Notes payable (net of current portion), net of discount		287,355			273,751
Long term debt (net of current portion)		168,029			181,457
Total Liabilities		3,068,241			2,592,056
Commitments and Contingencies (see Note 8)
Stockholders' Equity:
Common stock ($0.001 par value, 75,000,000 shares authorized,
46,511,409 shares and 39,054,867 issued and outstanding at
June 30, 2013 and  December 31, 2012, respectively)		46,511			39,055
Additional paid-in capital		4,150,511			2,738,545
Subscription receivable		-			(5,000	)
Accumulated deficit		(4,116,686	)		(2,584,798	)
Total Stockholders' Equity		80,336			187,802
Total Liabilities and Stockholders' Equity	$	3,148,577		$	2,779,858

The accompanying unaudited notes are an integral part of these unaudited condensed consolidated financial statements.

1

HEALTH REVENUE ASSURANCE HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

	(for the three months ended)						(for the six months ended)
	June 30,			June 30,			June 30,			June 30,
	2013			2012			2013			2012
Revenues	$	2,067,464		$	1,028,266		$	4,224,061		$	1,634,096
Cost of Revenues		975,632			453,233			1,960,952			884,352
Gross Profit		1,091,832			575,033			2,263,109			749,744
Operating Expenses
Selling and administrative expenses (includes stock compensation of $70,048 and $0 in 2013 and 2012, respectively)		1,941,675			1,047,334			3,385,759			1,656,605
Research and development		-			20,920			289			53,133
Depreciation and amortization		19,169			12,879			44,598			22,750
Total Operating Expenses		1,960,844			1,081,133			3,430,646			1,732,488
Operating Loss		(869,012	)		(506,100	)		(1,167,537	)		(982,744	)
Other Income (Expense)
Other income, net		635			-			351			-
Interest expense		(228,684	)		(4,922	)		(364,702	)		(10,842	)
Total Other Income (Expense), net		(228,049	)		(4,922	)		(364,351	)		(10,842	)
Loss before provision for income taxes		(1,097,061	)		(511,022	)		(1,531,888	)		(993,586	)
Provision for income taxes		-			-			-			-
Net Loss	$	(1,097,061	)	$	(511,022	)	$	(1,531,888	)	$	(993,586	)
Net Loss Per Share
basic and diluted	$	(0.02	)	$	(0.01	)	$	(0.03	)	$	(0.03	)
Weighted Average Number of Shares Outstanding
basic and diluted		45,422,517			35,229,195			44,763,302			35,229,195

The accompanying unaudited notes are an integral part of these unaudited condensed consolidated financial statements.

2

HEALTH REVENUE ASSURANCE HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

(for the six months ended)

	June 30,			June 30,
	2013			2012
Cash flows from Operating Activities:
Net loss	$	(1,531,888	)	$	(993,586	)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization		44,598			22,750
Stock issued for compensation		70,048			-
Amortization of debt discount		209,915			2,198
Bad debt expense		6,450			-
Change in operating assets and liabilities:
Accounts receivable, net		(270,326	)		(304,609	)
Prepaid expenses		26,924			21,680
Other assets		(12,140	)		(1,124	)
Accounts payable		130,555			309,826
Unearned revenue		-			52,069
Accrued liabilities		239,414			-
Net Cash used in operating activities		(1,086,450	)		(890,796	)
Cash flows from Investing Activities:
Capitalization of internally developed software		(681,372	)		-
Purchases of property and equipment		(7,732	)		(21,175	)
Net Cash used in investing activities		(689,104	)		(21,175	)
Cash flows from Financing Activities:
Borrowings (Repayments) on line of credit, net		(34,738	)		51,500
Settlement payments		(92,222	)		-
Loan proceeds		1,220,000			-
Loan proceeds from factor, net		(274,636	)		-
Repayments of debt obligations		(383,125	)		(17,629	)
Issuance of stock for cash net of offering cost		618,000			818,337
Net Cash provided by financing activities		1,053,279			852,208
Net decrease in cash		(722,275	)		(59,763	)
Cash at beginning of period		893,458			198,500
Cash at ending of period	$	171,183		$	138,737
Supplemental schedule of cash paid during the period for:
Interest	$	295,950		$	14,898
Income Taxes	$	-		$	-
Supplemental schedule of non-cash investing and financing activities:
Issuance of stock to repay debt	$	-		$	563,907
Capital lease obligation incurred for use of equipment	$	28,701		$	38,704
Beneficial conversion feature on convertible debt charged to additional paid in capital	$	-		$	300,000
Shares issued as a loan fee	$	679,353		$	-
Financed Equipment purchases	$	54,105		$	-
Insurance premium finance contract recorded as prepaid asset	$	57,573		$	-
Prepaid common stock issued for services	$	57,021		$	-

The accompanying unaudited notes are an integral part of these unaudited condensed consolidated financial statements.

3

HEALTH REVENUE ASSURANCE HOLDINGS, INC.

NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013 (UNAUDITED)

1 – NATURE OF BUSINESS AND GOING CONCERN

Overview

Health Revenue Assurance Holdings, Inc. (the “Company”) is a trusted source of timely, accurate and critical resources, technology and information that supports the performance of revenue integrity in assuring the existence of healthcare organizations. The Company and its subsidiaries’ products and services include business intelligence technology solutions, contract coding, billing, coding and compliance audits, education, revenue cycle consulting, physician services and ICD-10 transition services. The Company provides customized solutions to its clients with the highest regard for ethical standards and responsibility.

Dream Reachers, LLC, owns the Company’s offices and is the borrower on a mortgage loan related to such offices. Dream Reachers, LLC does not engage in real estate rental business. Its offices are occupied by Health Revenue Assurance Associates, Inc. (“HRAA”) at no cost and HRAA pays the related mortgage’s principal and interest, taxes and maintenance. The Company’s subsidiary HRAA is the sole member effective May 2011. Dream Reachers has been treated as a Subsidiary for accounting purposes in the Company’s unaudited condensed consolidated financial statements for all periods presented. (see Note 2)

Going Concern

The Company’s future success is dependent upon its ability to achieve profitable operations and generate cash from operating activities, and upon additional financing, Management believes they can raise the appropriate funds needed to support their business plan and develop an operating company which is cash flow positive.

However, as of June 30, 2013, the Company has an accumulated deficit and for the three and six months ended June 30, 2013, incurred net losses, and has used net cash in operations. The Company has not been able to generate sufficient cash from operating activities to fund its ongoing operations. There is no guarantee that the Company will be able to generate enough revenue and/or raise capital to support its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability or classification of recorded assets and liabilities that might result should the Company be unable to continue as a going concern.

As of June 30, 2013 the Company has a cash balance of approximately $171,000. The Company is currently addressing the going concern and liquidity issues. The Company expects an increase in cash flow as the result of a growing customer demand for medical billing, IT consulting, training, education and software products and services. In addition, the Company is evaluating financing opportunities through either equity or debt financing or a combination of both. 

2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.

Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (all of which are of a normal recurring nature) considered necessary for a fair presentation have been included. Operating results for the three months ended June 30, 2013 are not indicative of the results that may be expected for the year ending December 31, 2013 or for any other future period. These unaudited condensed consolidated financial statements and the unaudited notes thereto should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2013 (our “10-K”).

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Health Revenue Assurance Associates, Inc. and Dream Reachers, LLC. All significant inter-company transactions and balances are eliminated in consolidation.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements.  Actual results could differ from those estimates. Significant accounting estimates reflected in the Company’s consolidated financial statements include valuation of accounts receivable, valuation of property and equipment, valuation and amortization period of software, valuation of beneficial conversion features in convertible debt, valuation of equity based instruments issued for other than cash, revenue recognition, and the valuation allowance on deferred tax assets.

4

HEALTH REVENUE ASSURANCE HOLDINGS, INC.

NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013 (UNAUDITED)

Cash

For purposes of the statement of cash flows, the Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company’s cash balances are maintained at various banks that are insured by the Federal Deposit Insurance Corporation subject to certain limitations.

Accounts Receivable and Factoring

Accounts receivable are stated at the amounts management expects to collect.  An allowance for doubtful accounts is recorded using a specific identification method based on a combination of historical experience, aging analysis and information on specific accounts.  Account balances are written off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.  Management has determined that no allowance is required at June 30, 2013. The Company accounts for its factoring arrangements as either a sale or a secured financing based on the criteria in ASC 860 "Transfers and Servicing".  Estimates of allowances for doubtful accounts are reflected as a recourse obligation, a liability, for factor arrangements treated as a sale with recourse or as a contra asset accounts receivable allowance account for arrangements accounted for as a secured financing.

Software

Costs incurred in connection with the development of software products are accounted for in accordance with the Financial Accounting Standards Board Accounting Standards Codification ("ASC") 985  Costs of Software to Be Sold, Leased or Marketed.”   Costs incurred prior to the establishment of technological feasibility are charged to research and development expense. Software development costs are capitalized after a product is determined to be technologically feasible and is in the process of being developed for market and capitalization ceases after the general release of the software. Amortization of capitalized software development costs begins upon initial product shipment after general release. Capitalized software development costs are amortized over the estimated life of the related product (generally thirty-six months) using the straight-line method. The Company evaluates its software assets for impairment whenever events or change in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of software assets to be held and used is measured by a comparison of the carrying amount of the asset to the future net undiscounted cash flows expected to be generated by the asset.  If such software assets are considered to be impaired, the impairment to be recognized is the excess of the carrying amount over the fair value of the software asset. 

Software maintenance costs are charged to expense as incurred. Expenditures for enhanced functionality are capitalized. The cost of the software and the related accumulated amortization are removed from the accounts upon retirement of the software with any resulting loss being recorded in operations.  No amortization expense was recorded in the accompanying unaudited consolidated financial statements as of June 30, 2013 since our first software product was released on July 15th.

Fair Value Measurements and Fair Value of Financial Instruments

Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques.  Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy:

● Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets;

● Level 2—Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities; and

● Level 3—Unobservable inputs that are supported by little or no market activity that is significant to the fair value of assets or liabilities.

5

HEALTH REVENUE ASSURANCE HOLDINGS, INC.

NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013 (UNAUDITED)

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

Revenue Recognition

The Company recognizes services revenue based on the proportional performance method of recognizing revenue.

A portion of the Company’s revenue is generated from medical coding audit services. Auditing revenue is invoiced in accordance with the contract, generally at three benchmark time periods which coincide with when specific, obligatory field work services have been rendered and completed, the value of this portion of the contract price has been predetermined and agreed upon, and the client has received benefit or value in the form of the independent identification of system weaknesses and risk analysis. Further, collectability is reasonably assured due to the existence of a fixed fee contract and the size and financial health of the Company’s clients. Below is a description of the general benchmarks and work phases associated with the Company’s audit services:

● Planning Phase - work commences prior to and as soon as the contract is signed and includes setting the audit scope, scheduling of the job, assignment of audit staff, understanding the client and their systems, determination of sample size and sampling methods to be employed, and other specific items as outlined in the contract. The planning phase includes the determination of deliverables as defined in the contract, generally consisting of a listing of errors, training and a final report. The Company generally invoices and recognizes 50% of the contract value at the completion of the Planning Phase. Although all of the contracts contain a clause making the first 50% of the engagement fee due and non-refundable at this point, the Company does not deem this initial fee to be recognized as deferred revenue under SAB 104 due to the extensive amount of work to be done prior to accepting the contract.

● Field Work Phase – is performed at the client location and generally lasts one week and encompasses actual testing of sample claims preselected in the Planning Phase. The auditor generally preloads the selected claims into the Company’s proprietary software and audits the claim records by reviewing actual medical records. The software assists the auditor in determining proper classifications and allows the auditor to compare the proper classification against what was filed in the submission made by the client to Medicare. Notes and comments are recorded and audit reports are generated. The Company generally invoices and recognizes 40% of the contract value at the completion of the Field Work Phase.

● Reporting Phase – includes a summary of audit findings, exit conference with clients, and any other specific deliverables as determined by the contract. The Company generally invoices and recognizes the remaining 10% of the contract value at the completion of the Report Phase. 

A portion of the Company’s revenue is derived from consulting, training and coding services provided. Revenue from these revenue streams is recognized after services are performed based on the quoted and agreed upon fee contained in its contracts.

For our education products sold on a self-study standalone basis or in multiple element contracts which include training and the product and training are separable elements  (see below) revenue is recognized for the product upon passing of title which occurs once the end user is granted access to our online curriculum courses.

On July 15th the Company issued a general release for one of its products Visualizer ™. Additional product releases are anticipated to be for general availability during the 4th quarter of 2013.  Software sales on a standalone basis will be recognized upon delivery of the software when evidence of the purchase arrangement exists and the price is determinable, and when collectability is reasonably assured.

Arrangements with customers may involve multiple elements including software products, education products, training, software product maintenance, coding services, coding audit services and other consulting services. Training on education products will occur after the education product sale. Education products are sold and may be used as a self-study product, although most of our customers elect to purchase our training services and therefore most of our contracts to date are multiple element contracts including one price for the education product and related training. We allocate the selling price to each element as discussed below. Training and maintenance on software products will generally occur after the software product sale. Other services may occur before or after the product sales and may not relate to the products.  Revenue recognition for multiple element arrangement is as follows:

Each element is accounted for separately when each element has value to the customer on a standalone basis and there is Company specific objective evidence of selling price of each deliverable. For revenue arrangements with multiple deliverables, the Company allocates the total customer arrangement to the separate units of accounting based on their relative selling prices as determined by the price of the items when sold separately. Once the selling price is allocated, the revenue for each element is recognized using the general and specific criteria under GAAP as discussed above for elements sold in non-multiple element arrangements. A delivered item or items that do not qualify as a separate unit of accounting within the arrangement are combined with the other applicable undelivered items within the arrangement. The allocation of arrangement consideration and the recognition of revenue is then determined for those combined deliverables as a single unit of accounting.  The Company has historically sold its services with established rates which it believes is Company specific objective evidence of selling price. For the new software products, management has established selling prices which qualifies as Company specific objective evidence of selling price. Generally all elements in multiple element arrangements with Company customers qualify as separate units of account for revenue recognition purposes.

6

HEALTH REVENUE ASSURANCE HOLDINGS, INC.

NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013 (UNAUDITED)

Cost of Revenues

Cost of revenues includes labor costs for services and education development costs. There were no depreciation or amortization costs in 2013 or 2012 that were allocable to cost of sales. In future periods, amortization of capitalized software costs will be included in costs of revenues.

Earnings Per Share

The Company computes and presents earnings or losses per share in accordance with FASB ASC Topic 260, Earnings per share.  Basic earnings or losses per share are computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding.  Diluted earnings or loss per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares and common stock equivalents outstanding, calculated on the treasury stock method for options and warrants using the average market prices during the period.

As the Company incurred a net loss in all periods presented, all potentially dilutive securities were excluded from the computation of diluted loss per share since the effect of including them is anti-dilutive. There were no dilutive securities outstanding at June 30, 2013 and 2012 respectively.

Recent Accounting Pronouncements

We have implemented all new accounting standards that are in effect and that may impact our unaudited condensed consolidated financial statements and do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our consolidated financial position or results of operations.

3 - ACCOUNTS RECEIVABLE

Accounts receivable at June 30, 2013 and December 31, 2012 was as follows:

	June 30,		December 31,
	2013		2012
Accounts receivable	$	1,510,690	$	1,246,814
Allowance for doubtful accounts		-		-
Total	$	1,510,690	$	1,246,814

We had $6,450 and $0 in bad debt expense on trade accounts receivable for six months ended June 30, 2013 and 2012, respectively. (See Note 8)

4 – RESEARCH AND DEVELOPMENT AND SOFTWARE

Early 2012, the Company started developing the Visualizer™ suite. This intuitive and easy to use business intelligence product is designed to meet the emerging need for healthcare analytics. Customer data is infused into the suite, and the Company uses this to develop pre-defined analytics targeted to address healthcare’s emerging concerns and needs.

HRAA’s Visualizer™ suite will encompass multiple offerings. The first project currently under development is ICD Visualizer™, which assists healthcare leaders with their need to understand the exponential impact of the transition to ICD-10 including work flow, productivity, process changes and documentation and reimbursement risks. The application helps to visualize the reimbursement and operational effects of transitioning organizations to ICD-10 and identify where to focus education and documentation issues. It enables clients to develop a custom work plan to mitigate risks from the highest areas of exposure to the least.

The transition to ICD-10 is causing a paradigm shift in healthcare. In response, we have developed a new product called OMC Initiator (Outsourced Medical Coding) for processing healthcare claims within hospitals. This product captures data from the physician or the hospital’s financial systems and correlates the data in a manner that expedites the processing of a claim. To validate our new product, our team of Emergency Department Coders (ED Coders) is continuously evaluating the process of coding claims in order to enhance our product.

At June 30, 2013, the Company had accumulated a total of $940,305 in capitalized costs related to the development of the Visualizer™ suite and the OMC Initiater which is included as Software on the accompanying consolidated balance sheet.

7

HEALTH REVENUE ASSURANCE HOLDINGS, INC.

NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013 (UNAUDITED)

Amortization expense for software, for the three months ended June 30, 2013 and 2012 was $0, respectively as the Company has yet to have a general release of either product. Software consisted of the following at June 30, 2013 and December 31, 2012:

	June 30, 2013		December 31, 2012
Software	$	940,305	$	258,933
Accumulated amortization		-		-
Software, net	$	940,305	$	258,933

The following is a schedule of estimated future amortization expense of software at June 30, 2013 (assumes amortization begins July 15, 2013 and a three-year amortization period):

Estimated amortization expense of software is as follows:
July 1, 2013 through December 31, 2013	$	156,717
2014		313,435
2015		313,435
2016		156,718
TOTAL	$	940,305

5 – LINES OF CREDIT

Bank

The Company has a $150,000 revolving line of credit with a bank, effective in December 2008, for its general working capital needs. The line of credit is secured by all business assets, collateral, and personal guarantees. The line of credit has a maturity date of December 18, 2018. The interest rate per year is equal to the Bank’s Prime Rate plus 6.50 percent. The Bank’s prime rate of interest at June 30, 2013 was 3.25%. The balance due at June 30, 2013 was $137,500 with $25,863 reflected as a current portion. The first of seventy-two payments of $3,255 initiated January 18, 2013 and will continue through 2018.

Dell

The Company maintains a Dell Business Credit line of up to $50,000.  Interest rates vary under the line based on difference types of payment plans.  The balance due under the line as of June 30, 2013 was $48,928, which is included in line of credit, current portion in the accompanying unaudited condensed consolidated financial statements.

6 – LONG TERM DEBT AND NOTES PAYABLE

Long Term debt:

Long Term debt consisted of the following at June 30, 2013:

	June 30, 2013		December 31, 2012
Bank term loan	$	23,229	$	38,897
Mortgage loan		177,410		180,073
		200,639		218,970
Less current portion		(32,610)		(37,513	)
Total long term portion	$	168,029	$	181,457

The Company has a term loan with a bank whose proceeds were used for general working capital needs (the “Term Loan”).  The Term Loan was established in March 2009 as a result of a conversion of a revolving line of credit.  The Term Loan is personally guaranteed by one of the Company’s stockholders and is collateralized by the assets of the Company.  Payments of principal and interest are approximately $2,700 per month. The Term Loan matures in five years and incurs interest at the rate of 6.75% per annum.  Balance due as of June 30, 2013 was approximately $25,500 and is included in the long term debt, current portion line item in the accompanying unaudited condensed consolidated balance sheet.

8

HEALTH REVENUE ASSURANCE HOLDINGS, INC.

NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013 (UNAUDITED)

The Company has a mortgage related to certain real estate which houses the Company’s main offices in Plantation, Florida.  The loan originated July, 2010 in the amount of $192,500 and matures July 2020, when a balloon principal payment of approximately $129,000 becomes due.  The loan is collateralized by the real estate and is personally guaranteed by a principal stockholder of the Company. Interest is fixed at 6.625% for the first five years of the loan, and converts to an adjustable rate for the second five years at the Federal Funds Rate plus 3.25%, as established by the United State Federal Reserve. The balance under this mortgage loan as of June 30, 2013 was approximately $177,500 and is allocated to the current and long term debt line items in the accompanying unaudited condensed consolidated balance sheet. Monthly payments for principal and interest are approximately $1,500 until July 2015, when the total monthly payment may vary due to the adjustable interest rate provision in the note.

Notes payable:

In December 2012, the Company entered into loan agreements with various investors and issued promissory notes upon receipt of $815,000. The loan agreements have an interest rate of 12% per annum.  Principal and interest is payable over 26 months. Additionally, in connection with the financing, the Company issued 2,375,000 shares of common stock to the lenders as loan fees. The fair value per share of $0.28 (based on recent cash sales prices) was used to compute the relative fair value of the shares in accordance with ASC 470-20 which totaled $343,500 which was recorded as a debt discount with a credit to additional paid-in-capital and such discount is being amortized over the term of the loans. The unamortized discount was $259,423 as of June 30, 2013.

In January and February 2013, the Company entered into loan agreements with various investors and issued promissory notes upon receipt of $1,220,000. The loan agreements have an interest rate of 12% per annum.  Principal and interest is payable over 26 months. Additionally, in connection with the financing, the Company issued 5,575,000 shares of common stock to the lenders as loan fees (See note 9). The fair value per share of $0.28 (based on recent cash sales prices) was used to compute the relative fair value of the shares in accordance with ASC 470-20 which totaled approximately $679,500 which was recorded as a debt discount with a credit to additional paid-in-capital and such discount is being amortized over the term of the loans. The unamortized discount was $548,708 as of June 30, 2013.

The Company began paying principal and interest on the above mentioned notes in early 2013 in accordance with the payment terms.

Notes payable consisted of the following at June 30, 2013:

	June 30, 2013
Principal amount of notes payable	$	1,670,204
Unamortized discount		(808,131	)
Notes payable, net of discount		862,073
Less current portion		(574,718	)
Total Long term portion	$	287,355

7 – FACTORING AGREEMENT

In June 2012, the Company entered into a one-year factoring agreement with a finance company.  The agreement automatically renews annually unless terminated by either party. Under the terms of the agreement, the Company, at its discretion, assigns the collection rights of its receivables to the finance company in exchange for an advance rate of 85% of face value.  The assignments are transacted with recourse only at the option of the finance company in the event of non-payment.  The Company's obligations under the factor agreement are secured by substantially all assets of the Company.  In accordance with ASC 860 "Transfers and Servicing" regarding transfers of receivables with recourse, this factoring arrangement is accounted for as a secured financing. For the three months ended June 30, 2013, the Company had factored approximately $1,274,000 of receivables and had received cash advances of approximately $1,083,000. Outstanding receivables purchased by the factor as of June 30, 2013 were approximately $635,000 and are included in accounts receivable in the accompanying unaudited condensed consolidated balance sheet, and the secured loan due to the lender was approximately $552,500. Factor fees for the three months ending June 30, 2013 were approximately $31,000, and are included in interest expenses. (See Note 3)

9

HEALTH REVENUE ASSURANCE HOLDINGS, INC.

NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013 (UNAUDITED)

8 – COMMITMENTS AND CONTINGENCIES

Commitments

Leases:

In September 2012, the Company started a non-cancelable operating lease for office equipment.  The lease term is 5 years. Lease payments during the five years are approximately $500 per month.

On September 1, 2011, the Company entered into a commercial lease agreement for additional office space.  The lease term is one year with five successive one year renewal options. Starting September 1, 2012, the lease has been renewed for one year with a fixed payment of approximately $5,008 per month. For each year thereafter of the initial year, the rent will be subject to an increment of 4%.

Capital Leases:

The Company leases its property and equipment from Dell Financial Services L.L.C. under a capital lease. The economic substance of the lease is that the Company is financing the acquisition of the assets through the lease and accordingly, it is recorded in the Company’s assets and liabilities.

The following is an analysis of the leased assets included in Property and Equipment:

	June 30, 2013
Equipment		70,670
Less accumulated depreciation		(20,405	)
Total	$	50,265

The lease agreement contains a bargain purchase option at the end of the lease term.

The following is a schedule by years of future minimum payments required under the lease together with their present value as of June 30, 2013:

Year Ending December 31:
2013	$	14,353
2014		28,706
2015		18,467
2016		983

Total minimum lease payments		62,509
Less amount representing interest		(9,972	)
Present value of minimum lease payments	$	52,537

Amortization of assets held under capital leases is included with depreciation expense and is approximately $20,500 as of June 30, 2013.

Settlement Agreement:

On May 8, 2012, the Company terminated the employment of our Chief Marketing Officer (“CMO”) and subsequently amended its complaint to enforce certain non-competition clauses contained in the employment agreement. The Company sought a declaration of its obligations to pay severance under the terms of its then-existing employment agreement with the CMO.

On July 9, 2012, the Company and the former CMO entered into a Settlement Agreement to resolve two pending lawsuits arising out of the termination of his employment agreement. The lawsuit was initiated by the Company against the former CMO in the United States District Court for the Southern District of Florida.  In addition, the former CMO sued the Company in the United States District Court of the District of Colorado.

Pursuant to the Settlement Agreement, the former CMO agreed to abolish all claims and lawsuits against the Company and its CEO and COO and resigned any and all positions which he had or presently may have had with the Company. As part of the Settlement Agreement, the Company agreed to make eleven (11) payments totaling $232,500 pursuant to the terms of his prior employment agreement. Additionally, the CMO agreed to transfer his 3,299,802 shares to an officer of the Company in 2012. These payments commenced July 2012, and the outstanding balance as of June 30, 2013 was $23,056. In addition, the Company has agreed to abolish all claims and lawsuits against the former CMO.  The Settlement Agreement has a seven (7) day grace period for payments to the former CMO, after which time, he may seek court intervention to enforce the payments.  The Company's Chief Executive Officer and Chief Operating Officer, respectively, have personally guaranteed the payments of the Settlement Agreement. As a result of the Settlement Agreement, both parties are dismissing their respective filings and have agreed to not enter any more lawsuits concerning the scope of this matter. The remaining balance due is included in the accompanying balance sheets as settlement payable.

Employment Agreements:

From time to time, the Company enters into employment agreements with certain of its employees.  These agreements typically include bonuses, some of which are performance-based in nature. As of June 30, 2013, no performance bonuses have been earned. The Company owes its CEO $75,000 as stated in the February 2012 merger agreement, which is accrued in the accompanying unaudited condensed consolidated Financial Statements as Due to officer.

Contingencies

From time to time, the Company is involved in litigation matters relating to claims arising from the ordinary course of business. While the results of such claims and legal actions cannot be predicted with certainty, the Company’s management does not believe that there are claims or actions, pending or threatened against the Company, the ultimate disposition of which would have a material adverse effect on our business, results of operations, financial condition or cash flows.

10

HEALTH REVENUE ASSURANCE HOLDINGS, INC.

NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013 (UNAUDITED)

9 – STOCKHOLDERS' EQUITY

Common Stock

On January 15, 2013, the company raised $13,000 through the issuance of 46,429 shares of common stock at a price per share of $0.28 per share.

On January 31, 2013, the company issued 50,266 shares of common stock as compensation to an employee for services rendered through March 31, 2013. The shares were valued at $0.49 per share based on the quoted trading price per share or $24,630 which was expensed.

On February 2013, the Company issued 5,575,000 shares of common stock in connection with a financing transaction as more fully described in note 6.

On March 2013, the Company entered into a one-year agreement with a consultant for 230,000 vested shares and cash consideration.  The shares were valued on the agreement date which was the measurement date at $0.35, based on the quoted trading price and the $80,500 is being expensed over the term of the contract.  The shares were issued on April 4, 2013 to the consultant. During the three months ending June 30, 2013, the company expensed and additional $20,125 and recorded $57,021 as prepaid expense in connection with this transaction.

On April 1, 2013, the company issued 54,847 shares of common stock as compensation to two employees for services rendered through June 30, 2013. The shares were valued at $0.40 per share based on recent cash sales by the Company or $21,939 which was expensed.

On May 19, 2013, the Company raised $250,000 through the issuance of 625,000 shares of common stock at a price per share of $0.40 per share.

On May 29, 2013 and June 21, 2013, the Company raised $50,000 and $300,000 through the issuance of 125,000 and 750,000 shares of common stock at a price of $0.40 per share.

10 – CONCENTRATIONS

Sales to thirteen hospitals represented approximately 49% of net sales for the three months ended June 30, 2013. Wherein, seven and six hospitals respectively are part of two larger health systems.  The company has direct relationships with both the individual hospitals and the health systems.  As such, the strength of the relationship is driven by the individual hospitals.

Sales to four customers were approximately 66% of revenue for the three months ended June 30, 2013.

Two and three vendors represented approximately 59% and 68% of the outstanding accounts payable balance as of June 30, 2013 and December 31, 2012, respectively.

Two customers represented approximately 41% and 62% of the accounts receivable as of June 30, 2013 and December 31, 2012 respectively.

11 – SUBSEQUENT EVENTS

During July and August pursuant to private placements, the Company issued 1,000,000 shares of common stock for cash with a per share price of $0.40 per share or $ 400,000

11

HEALTH REVENUE ASSURANCE HOLDINGS, INC.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of the results of operations and financial condition of Health Revenue Assurance Holdings, Inc. for the three and six months ended June 30, 2013 and 2012, should be read in conjunction with the Selected Consolidated Financial Data, Health Revenue Assurance Holdings’ financial statements, and the notes to those financial statements that are included elsewhere in this Quarterly Report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under the Cautionary Notice Regarding Forward-Looking Statements in this Quarterly Report. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements.

Overview

On February 10, 2012, Health Revenue Assurance Holdings, Inc. (the “Company” or “HRAH”) entered into an Agreement and Plan of Merger and Reorganization with Health Revenue Acquisition Corp., a Maryland corporation and our wholly-owned subsidiary (“Acquisition Sub”), and Health Revenue Assurance Associates, Inc., a Maryland corporation (“HRAA”), pursuant to which Acquisition Sub was merged with and into HRAA, and HRAA, as the surviving corporation, became our wholly-owned subsidiary (the “Merger”).

HRAA improves the healthcare delivery experience for doctors, nurses and patients while assuring the existence of healthcare organizations.  Since 2001, we have been providing Revenue Integrity programs for healthcare organizations across the country and are committed to providing the most intuitive and effective solutions in the industry. HRAA’s products and services include business intelligence technology solutions, contract coding, billing, coding and compliance audits, education, revenue cycle consulting, physician services and ICD-10 transition services.  Our collaborative approach provides the right solutions for our clients’ needs with the highest regard for ethical standards and responsibility.

On April 13, 2012, the Board unanimously approved a change in the Company’s name from Anvex International, Inc. to Health Revenue Assurance Holdings, Inc. to be consistent with our current business following the Merger.

We are subject to risks common to service providers and consulting companies, including competition and the ability to recruit, train, and put in place a sufficient quantity of proficient consultants and medical coders familiar with the requirements of IDC-10-CM/PCS, the uncertainty of future regulatory approvals and laws, the need for future capital and the retention of key employees. We cannot provide assurance that we will generate revenues or achieve and sustain profitability in the future.

Recent Developments

Certain significant items or events must be considered to better understand differences in our results of operations from period to period. We believe that the following items have had a material impact on our results of operations for the periods discussed below or may have a material impact on our results of operations in future periods.

ICD-10 Transition

In the short term, the main focus of our business will be with respect to the ICD-10 coding transition. In that regard, our potential clients are all hospitals and medical providers which currently maintain coding personnel in some form that are primarily responsible for seeking reimbursement for patients’ procedures. The current system in place that drives the appropriate medical codes from hospitals/medical facilities to insurance companies is called ICD-9, which was implemented over 30 years ago.

In January 2009, the United States Department of Health and Human Services (“HHS”) published a final rule which mandated a change in medical coding in United States health care settings from the current system, International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM), to the International Classification of Diseases, 10th Edition, Clinical Modification/Procedure Coding System (ICD-10-CM/PCS). Compliance with this ruling was to be achieved by October 1, 2013.  The new, mandated version expands the number of codes from 24,000 to 155,000, making it more precise and descriptive and more accurately describing the diagnoses and inpatient procedures of care delivered.  The transition to ICD-10-CM/PS will require significant business and systems changes throughout the health care industry and will impact all processes and people from finance to compliance to doctors.  

On April 9, 2012, as published in the Federal Register, citing concerns about the ability of provider groups to meet the looming compliance deadline to adopt ICD-10-CM/PCS, HHS announced a proposed rule which would delay the implementation date to October 1, 2014.  Interested parties had the ability to comment during a period ending 30 days after the date of the announcement. On August 27, 2012, HHS Secretary Kathleen Sebelius announced the release of a rule that makes final a one-year proposed delay—from October 1, 2013, to October 1, 2014 — in the compliance date for the industry's transition to ICD-10 codes.

12

The Company anticipates implementation of ICD-10-CM/PCS to be completed by the newly proposed effective date of October 1, 2014.

We believe that we are capable of providing consulting and related services with respect to the ICD-10 coding transition and the potential issues that we believe medical providers will experience due to the transition. In that regard, we believe the following are some of the issues that will be experienced due to the changeover:

● The new system will require time, money and commitment by over 6,000 hospitals, 600,000 physicians and every health insurance provider in the United States.

● Re-education and training of every Health Information Management (“HIM”) department is required of every hospital and medical facility in the United States.

● All claims submitted by hospitals and physicians for reimbursement without utilizing ICD-10 will result in immediate rejection and non-payment.

HRAA’s vision regarding ICD-10 Transition:

● Hospitals and medical facilities will incur massive backlogs in their billing and coding departments.  Backlog in coding will lead to greater time between payments and crippling financial deficits.

● There will likely be an increase in coding errors, resulting in incorrect payments that can lead to hefty fines.

● Initial estimates based on other countries that have already converted to ICD-10 predict a 50% loss of productivity due to the complexity of the new system - a result of more time being allocated to the preparation of each individual patient case.

● The sheer number of codes and time for each entry will dramatically impact the workload.  Currently there are not enough coders to meet this demand, resulting in an ongoing shortfall, with an accelerating shortfall anticipated after ICD-10 is implemented.

● Every discipline in the hospital will be affected as they all revolve around the same coding system.

● For each code in the ICD-9 format, there will be additional, more descriptive codes in the ICD-10 format. This will greatly increase the quality of patient care, but simultaneously put a burden on hospitals and their medical coders.

● Currently under ICD-9, hundreds of millions of dollars of revenue are lost each year due to medical coding and billing errors.

● The average age of a medical coder is 54. It is estimated that 20% of coders plan to retire or change activities because of this transition.

HRAH Chairman, CEO and Founder Andrea Clark, RHIA, CCS, CPC-H, continues to build the Company to meet the changing needs of the healthcare community and her accomplishments continue to be acknowledged. A few recent awards include:

● “Female Executive of the Year” Gold Award Winner - Stevie Awards for Women in Business – December, 2012

● "Maverick of the Year” Bronze Award Winner - Stevie Awards for Women in Business – December, 2012

● “Mentor of the Year" - 2012 AHIMA Triumph Awards – June, 2012

● “10 HIM Heroes, Professionals Who Have Made a Difference" - For The Record Magazine – October, 2011

HRAA has also been recognized for tremendous growth and industry leadership. Recent acknowledgments include:

● “Fastest Growing Company of the Year”  Bronze Award Winner- Stevie Awards for Women in Business – December, 2012

● “Top Ten Best Places To Work” - South Florida Business Journal – 2011  

We believe we are able to provide hospitals and medical providers with the ability to effectively transition to ICD-10 and prevent massive backlogs that lead to crippling financial deficits.  Our team of certified coders provides hospitals with the expertise needed to successfully input the proper data set into the Health Information Management (HIM) system which drives reimbursement from insurance providers such as Medicare and Medicaid, as well as private insurance companies.  We offer above industry standards ICD-9 and ICD-10 training to coders, equipping them with the knowledge to effectively assign the appropriate codes. We also conduct medical billing audits, identifying risks of lost revenue and ensuring the correct amounts have been paid. In doing so, we shorten the revenue cycle and prevent financial stress on healthcare providers.

13

The transition from ICD-9 to ICD-10 is and will drastically affect the entire healthcare industry, especially patients, hospitals, medical facilities, physicians, insurance providers and the coding workforce. Our goal is to optimize revenue integrity by providing expert contract coding and consulting services to hospitals and medical facilities throughout the United States.  We will implement marketing tools in order to create our own brand identity and leverage this rapidly growing awareness of the upcoming switch to ICD-10 and the potential financial pressure a hospital will face if not properly prepared and trained.

We believe that the following tasks are essential to achieve ongoing success:

● development of long lasting relationships with new clients and strengthen relationships with existing clients;

● recruitment and proper training of qualified personnel;

● appropriate fiscal planning and execution;

● development of an extensive sales network;

● effective and broad-reaching promotional programs;

● connecting effectively with executive-level decision makers of hospitals and medical facilities;

● accurately and efficiently audit the medical billing records to maximize revenue integrity;

● ensure that we are supplying hospitals and medical facilities with top quality, certified medical coders;

● developing and deploying dynamic and effective marketing strategies; and

● informing healthcare professionals of the products, services and benefits of being an HRAA client.

In addition to the above, our ICD-10 coding transition services will also include the training of our client’s staff with respect to the ICD-10 coding system; providing coding resources while the client’s staff is undergoing training; coding resources to handle backlog as productivity levels drop off; and auditing resources to ensure retention and accuracy of the ICD-10 coding.

Products and Services

We provide our customers with customized, hands-on, strategy-focused and in-depth analysis of a hospital’s Revenue Cycle and their compliance, as well as APC and DRG coding and documentation audits. We also offer customized education and certification programs, charge master data integrity, reviews, and solutions yielding measurable results, increased productivity, reduced DNFB, improved APC accuracy and optimized Revenue Integrity. We are committed to providing the most intuitive Revenue Integrity solutions in the industry through various means including APC AuditPro™, our proprietary internal auditing technology for outpatient claims.

HRAA provides an in-depth analysis of a hospital’s revenue cycle and their compliance, and offers the only full suite of business intelligence products and consulting services required to keep up with the ever-changing healthcare industry. All of our products and services yield measurable results, increased productivity, reduced unbilled accounts, improved payment accuracy and provide optimized revenue integrity for hospitals and physicians.

Products

Healthcare is traversing a period of significant change with the dawning of Accountable Care Organizations (“ACOs”), the declaration of Meaningful Use, and probably the most important of these agents of change is the transition from ICD-9 to ICD-10. To understand the importance of these changes, healthcare’s decision makers need to recognize the impact these changes are having on their organizations. To do this they must visualize and analyze their available data to produce actionable results that improve the organization’s overall performance.

ICD-10 Education Curriculum

We provide our customers with an online internally developed education curriculum focused on ICD-10 CM Diagnosis and ICD-10-PCS Procedure course material.

Visualizer™

Visualizer™ is an analytic platform that provides healthcare decision makers with an integrated view of financial, operational, and clinical data across multiple sources of data. Each Visualizer ™ building block is designed to meet a specific analytic need.

OMC Initiator

The Outsourced Medical Coding Initiator was created for processing healthcare claims within hospitals. This product captures data from the physician or the hospital’s financial systems and correlates the data in a manner that expedites the processing of a claim. To validate our new product, our team of Emergency Department Coders (ED Coders) is continuously evaluating the process of coding claims in order to enhance our product.

Verifier™ (Inpatient and Outpatient)

Healthcare organizations need executable tactics that can be implemented up and down the revenue cycle, with both inpatients and outpatients. These steps taken must be clear and simple to really improve the patient experience. Creating a successful revenue integrity program will have the most immediate impact in that initiative. However, there is a significant challenge in today’s environment of complex regulations, changing payer requirements, and RAC, CERT, HIPAA along with ICD-10 pressures and increasing financial and workforce resource constraints.

Under the Center for Medicare and Medicaid Services’ (“CMS’”) value-based purchasing rules, hospitals will be assessed on quality performance, with clinical measures weighted at 70% and patient experience measures weighted at 30%. Verifier™ Suite is the most comprehensive solution for healthcare organizations performing internal auditing that provides insight into both clinical quality and service quality. This proven technology has been stress tested by HRAA providing internal auditing services to our clients for over 10 years. Although, conducting regular audits and taking a high level view of the reimbursement landscape is required, it’s not until you roll up your sleeves and start digging into the claim details, that you will uncover hidden revenue integrity issues.

14

Services

Coding Services

The HRAA coding solution provides hospitals and physicians across the United States with an experienced team of backlog coders to assist facility coding departments or provide outsourcing services. Certified HRAA associates supply hospitals and physicians with medical coding and billing expertise, while reducing the risk of error and maximizing accuracy, efficiency and profitability. Medical coding is the process of taking information from a wide variety of patient medical records, charts and notes, and converting it into an alphanumeric data set. The data set then drives the payment for the services rendered when submitted to Medicare, Medicaid, commercial payers and other healthcare providers. Medical coders analyze the documentation maintained within medical records and assign codes that drive reimbursement. Additionally, the data set is utilized as a collection methodology for tracking diseases, quality of care and treatment.

Billing & Coding Audits

HRAA’s team motivates excellence and reimbursement proficiency through customized, hands-on, strategy-focused and in-depth approach to the issues facing hospitals today and preparing them for tomorrow. While increasing profits for healthcare professionals remains a moving target, it is paramount to focus attention on compliant reimbursement dollars.

Education

We offer various training and educational opportunities to our clients, including Education Sessions, Coding Boot Camps, Workshops, and Webinars.

Consulting

We have specialized in building reimbursement proficiency by focusing on the entire revenue cycle, not just coding, and by providing RAC oriented audits, education and consulting services. Because our approach is to focus on the client’s needs and develop the solution on an individual basis, our team possesses extensive experience in revenue cycle issues. We focus not merely on the revenue and codes, but on their operational uses. HRAA’s consulting services provide secure and effective solutions for complex regulatory challenges, internal inefficiencies and revenue cycle analysis.

ICD-10 Transition Services

The transition to ICD-10 codes is not just a coding conversion; it is a change that impacts virtually all areas of the revenue cycle. HRAA’s unique approach to this business transition is multidimensional, providing organizations with a smooth and sustainable transition. HRAA offers “turn-key ICD-10 services” to assist clients with all aspects of the transition, with great emphasis on streamlined comprehensive training while maintaining productivity.

HRAA's ICD-10 Transition Services Include ICDVisualizer™, Needs Assessment, ICD-9/ICD-10 Dual Audit, Education, Reserved Medical Coder Personnel, Auditing, Continuous Support.

Business Intelligence

HRAA offers Business Intelligence Services to help clients interpret data and make healthcare organizations more efficient and effective.

HRAA Business Intelligence team offers a number of solutions including: Implementation of Visualizer™ Suite products, Deployment of solution templates, Development of custom applications. HRAA solution template offers the flexibility to customize the solution to meet client's needs without having to start application development from scratch.

HRAA's implementation experience of templates include: Surgery Center Analytics, Revenue Cycle Management, Customer satisfaction surveys, Hospital Statistics, Quality measures.

Physician Services

Certified coders and auditors are fully trained and are required to maintain continuing education each year to uphold their certification. HRAA is proactive providing each coder and auditor with many opportunities for additional training to make certain we are always providing the highest quality standard you expect from HRAA. HRAA takes each encounter through a rigorous review in-line with the documentation guidelines used by CMS.

The education that follows an audit includes the basic fundamentals of appropriate documentation for the levels of service billed. Physician will be introduced to the specific issues noted within the documented service. Recommendations on how to improve upon the documentation will be discussed, including template usage, appropriate EHR revisions, form creation, and so forth.

15

Three months ended June 30, 2013 compared to June 30, 2012

Results of Operations

The following table presents a summary of operating information for the three months ended June 30, 2013 and 2012:

	For the three months ended						Increase/			Increase/
	June 30, 2013			June 30,  2012			(Decrease) $			(Decrease) %
Revenue	$	2,067,464		$	1,028,266		$	1,039,198			101.06	%
Costs of Revenues		975,632			453,233			522,399			115.26	%
Gross profit		1,091,832			575,033			516,799			89.87	%
Selling and administrative expenses		1,941,675			1,047,334			894,341			85.39	%
Research and development expenses		0			20,920			(20,920)			(100.00	)%
Depreciation and amortization		19,169			12,879			6,290			48.84	%
Total operating expenses		1,960,844			1,081,133			879,712			81.37	%
Operating income (loss)		(869,012	)		(506,100	)		(362,912	)		71.71	%
Other expense, net		(228,049	)		(4,922	)		(223,127	)		4,533.25	%
Net loss	$	(1,097,061	)	$	(511,022	)	$	586,039			114.68	%

Revenue:

Revenue increased by $1,039,198 or approximately 101%, from $1,028,266 for the three months ended June 30, 2012 to $2,067,464 for the three months ended June 30, 2013.  The increase was due primarily to increased revenue generated as a result of an increase in business development and marketing efforts put forth by HRAA.

Cost of Revenues:

Cost of revenues increased by $522,399 or approximately 115%, from $453,233 for the three months ended June 30, 2012 to $975,632 for the three months ended June 30, 2013. The increase was due primarily to greater personnel and related training costs associated with the buildup of the Company’s audit and coding service provider personnel required to service the anticipated increase in service contracts in future periods. Specifically, as of June 30, 2013, the Company employed 114 service providers, who have to go through a period of training, as compared to 71 service providers as of June 30, 2012.

Gross profit:

Gross profit increased by $516,799, or approximately 90%, from $575,033 for the three months ended June 30, 2012 to $1,091,832 for the three months ended June 30, 2013.  The increase in gross profit was due to the increase in business experienced in the year.

Selling and Administrative Expenses:

Selling and administrative expenses were $1,941,675 for the three months ended June 30, 2013, an increase of $894,341 or 85%, from $1,047,334 for the three months ended June 30, 2012.  The change in the 2013 period compared to the 2012 period was primarily due to:

● Personnel costs have increased by approximately $641,000 or approximately 104%, from approximately $614,000 for the three months ended June 30, 2012 to approximately $1,255,000 for the three months ended June 30, 2013.  The increase is due primarily to increased compensation and related expenses associated with the buildup of the Company’s management, sales and administrative staff in anticipation of growth in business volume.

● Professional fees have increased from approximately $68,000 for the three months ended June 30, 2012 to approximately $186,000 for the three months ended June 30, 2013, an increase of approximately $118,000, or 173%.  This increase is attributable to legal, audit, consulting, and accounting services provided in connection with expenses associated with financial reporting matters.

● The remainder of the increase in Selling and administrative expenses is related to costs associated to the company’s business development such as marketing, trade shows and seminars.

16

Research and Development Expenses:

We had no research and development expenses for the three months ended June 30, 2013, a decrease of approximately $21,000, or 100%, for the three months ended June 30, 2012. The decrease is due to the capitalization of expenses related to the development of the Visualizer™ suite.

Depreciation and Amortization Expenses:

Depreciation and amortization expenses were approximately $19,000 for the three months ended June 30, 2013, an increase of approximately $6,000, or 49%, from approximately $13,000 for the three months ended June 30, 2012. The increase was primarily due to depreciation costs associated with the Company’s purchases for computer equipment necessary to support the increase in personnel.

Interest Expense (included in other expenses, net):

Interest Expense was approximately $228,000 for the three months ended June 30, 2013, an increase of approximately $223,000, from approximately $5,000 for the three months ended June 30, 2012. The increase is due to the factoring fees experienced in the quarter along with interest on outstanding debt obligations and amortization of debt discounts.

Net Income (loss):

As a result of the above factors, a net loss of approximately $1,097,000 was recognized for the three months ended June 30, 2013 as compared to net loss of approximately $511,000 for the three months ended June 30, 2012, an increase of approximately $586,000 or approximately 115%.  The increase in net loss is outlined above.

Six months ended June 30, 2013 compared to June 30, 2012

Results of Operations

The following table presents a summary of operating information for the six months ended June 30, 2013 and 2012:

	For the six months ended						Increase/			Increase/
	June 30, 2013			June 30,  2012			(Decrease) $			(Decrease) %
Revenue	$	4,224,061		$	1,634,096		$	2,589,965			158.5	%
Costs of Revenues		1,960,952			884,352			1,076,600			121.7	%
Gross profit		2,263,109			749,744			1,513,365			201.9	%
Selling and administrative expenses		3,385,758			1,656,605			1,729,153			104.4	%
Research and development expenses		289			53,133			(52,844	)		(99.5	)%
Depreciation and amortization		44,598			22,750			21,848			96.0	%
Total operating expenses		3,430,646			1,731,488			1,698,157			98.0	%
Operating income (loss)		(1,167,537	)		(982,744	)		(184,793	)		18.8	%
Other expense, net		(364,351	)		(10,842	)		(353,509	)		3,260.6	%
Net loss	$	(1,531,888	)	$	(993,586	)	$	538,302			54.52	%

Revenue:

Revenue increased by $2,589,965 or approximately 159%, from $1,634,096 for the six months ended June 30, 2012 to $4,224,061 for the six months ended June 30, 2013.  The increase was due primarily to increased revenue generated as a result of an increase in business development and marketing efforts put forth by HRAA.

Cost of Revenues:

Cost of revenues increased by $1,076,600 or approximately 122%, from $884,352 for the six months ended June 30, 2012 to $1,960,952 for the six months ended June 30, 2013. The increase was due primarily to additional  personnel and related training costs associated with the buildup of the Company’s audit and coding service provider personnel required to service the anticipated increase in service contracts in future periods. The Company employed 114 service providers as of June 30, 2013 as compared to 71 service providers as of June 30, 2012.

Gross profit:

Gross profit increased by $1,513,365, or approximately 202%, from $749,744 for the six months ended June 30, 2012 to $2,263,109 for the six months ended June 30, 2013.  The increase in gross profit was due to the increase in business experienced during the year.

Selling and Administrative Expenses:

Selling and administrative expenses were $3,385,758 for the six months ended June 30, 2013, an increase of $1,729,153 or 104.4%, from $1,656,605 for the six months ended June 30, 2012.  The change in the 2013 period compared to the 2012 period was primarily due to:

● Personnel costs have increased by approximately $1,215,000 or approximately 140%, from approximately $867,000 for the six months ended June 30, 2012 to approximately $2,082,000 for the six months ended June 30, 2013.  The increase is due primarily to increased compensation and related expenses associated with the buildup of the Company’s management, sales and administrative staff in anticipation of growth in business volume.

● Professional fees have increased from approximately $103,000 for the six months ended June 30, 2012 to approximately $321,000 for the six months ended June 30, 2013, an increase of approximately $218,000, or 212%.  This increase is attributable to legal, audit, consulting, and accounting services provided in connection with expenses associated with financial reporting matters.

● The remainder of the increase in Selling and administrative expenses is related to costs associated to the company’s business development such as marketing, trade shows and seminars.

17

Research and Development Expenses:

Research and development expenses were $289 for the six months ended June 30, 2013, a decrease of approximately $53,000, or 100%, for the six months ended June 30, 2012. The decrease is due to the capitalization of expenses related to the development of the Visualizer™ suite.

Depreciation and Amortization Expenses:

Depreciation and amortization expenses were approximately $44,600 for the six months ended June 30, 2013, an increase of approximately $21,900, or 96%, from approximately $22,700 for the six months ended June 30, 2012. The increase was primarily due to depreciation costs associated with the Company’s purchases for computer equipment necessary to support the increase in personnel.

Interest Expense (included in other expenses, net):

Interest Expense was approximately $364,000 for the six months ended June 30, 2013, an increase of approximately $353,000, from approximately $11,000 for the six months ended June 30, 2012. The increase is due to the factoring fees experienced during the year along with interest on outstanding debt obligations and amortization of debt discounts.

Net Income (loss):

As a result of the above factors, a net loss of approximately $1,532,000 was recognized for the six months ended June 30, 2013 as compared to net loss of approximately $994,000 for the six months ended June 30, 2012, an increase of approximately $538,000 or approximately 55%.  The increase in net loss is outlined above.

Non-GAAP – Financial Measures

The following discussion and analysis includes both financial measures in accordance with GAAP, as well as a non-GAAP financial measure.  Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position or cash flows that either excludes or includes amounts that are not normally included or excluded in the most directly comparable measure calculated and presented in accordance with GAAP.   Non-GAAP financial measures should be viewed as supplemental to, and should not be considered as alternatives to net income, operating income, and cash flow from operating activities, liquidity or any other financial measures.  They may not be indicative of the historical operating results of the Company nor is it intended to be predictive of potential future results.  Investors should not consider non-GAAP financial measures in isolation or as substitutes for performance measures calculated in accordance with GAAP.

We believe that both management and shareholders benefit from referring to the following non-GAAP financial measure in planning, forecasting and analyzing future periods. Our management uses this non-GAAP financial measure in evaluating its financial and operational decision making and as a means to evaluate period-to-period comparison. Our management uses and relies on the following non-GAAP financial measure:

Adjusted EBITDA from continuing operations

Our management believes Adjusted EBITDA from continuing operations is an important measure of our operating performance because it allows management, investors and analysts to evaluate and assess our core operating results from period to period after removing the impact of items of a non-operational nature that affect comparability.  Our management recognizes that Adjusted EBITDA from continuing operations, like EBITDA from continuing operations, has inherent limitations because of the excluded items.

We have included a reconciliation of our non-GAAP financial measures to the most comparable financial measure calculated in accordance with GAAP.  We believe that providing the non-GAAP financial measure, together with the reconciliation to GAAP, helps investors make comparisons between the Company and other companies.  In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measure to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measure and the corresponding GAAP measure provided by each company under applicable SEC rules.

18

The Company defines Adjusted EBITDA from continuing operations as earnings (or loss) before interest expense, income taxes, depreciation and amortization, and non-cash stock-based compensation.  The Company excludes stock-based compensation because it is non-cash in nature.  The following table presents a reconciliation of Adjusted EBITDA from continuing operations to Net Income (loss) from continuing operations allocable to common shareholders, a GAAP financial measure:

	For the three months ended
	June 30,  2013			June 30,  2012
Net loss	$	(1,097,061	)	$	(511,022	)
Interest expense		228,684			4,922
Depreciation and amortization		19,169			12,879
Stock based compensation expense		70,048			-
Adjusted EBITDA (loss) from operations	$	(779,160	)	$	(493,221	)

Liquidity and Capital Resources

The Company’s principal sources of liquidity include proceeds from long term debt and private placement of its shares. Overall, for the six months ended June 30, 2013, the Company generated approximately $1,838,000 from its financing activities primarily associated with the debt and equity financing.  Such proceeds, coupled with its beginning cash balances, were utilized by the Company to fund its negative cash flow from operating activities in the amount of approximately $1,086,000 and investment in property and equipment of approximately $689,000.

As of June 30, 2013, the Company had cash balances of approximately $171,000 as compared to approximately $139,000 as of June 30, 2012, an increase of approximately $32,000.

Net cash used in operating activities was approximately $1,086,000 for the six months ended June 30, 2013.  This compared to net cash used by operating activities of approximately $891,000 for the six months ended June 30, 2012. The increase of $195,000 was used to fund a net loss of $1,531,885 reduced by non-cash depreciation of $44,598, stock compensation expense of $70,048, amortization of debt discount of $209,915, bad debt of $6,450, and changes in operating assets and liabilities totaling $114,424.

Net cash used in investing activities for the six months ended June 30, 2013 was approximately $689,000 compared to approximately $21,000 for the six months ended June 30, 2012.  The increase is primarily attributable to the development of software.

Net cash provided by financing activities amounted to approximately $1,053,000 for the six months ended June 30, 2013, compared to net cash provided in the six months ended June 30, 2012 of approximately $852,000, representing an increase in net cash flow from financing activities of approximately $201,000.  This was due to the receipt of net proceeds from the Company’s issuance of stock, net borrowings from new and existing debt obligations, offset by various debt repayments.

Financing:

The Company has the following financing arrangements:

1. The revolving line of credit for $150,000 with Bank of America for working capital needs was modified on December 18, 2012. The loan no longer has an expiration date of December 18, 2012, but instead a final maturity date of December 18, 2018. The interest rate per year is equal to the Bank’s Prime Rate plus 6.5 percentage points. The Bank’s prime rate of interest at June 30, 2013 was 3.25%. First payment of $2,083 was paid January 18, 2013.

2. A term loan with Bank of America whose proceeds were used for general working capital. The loan is personally guaranteed by one of the Company’s stockholders and is collateralized by the assets of HRAA. Payments of principal and interest are approximately $2,700 per month. The loan matures in five years from September 2009, and incurs interest at the rate of 6.75% per annum. The balance due as of June 30, 2013 was approximately $23,300.

3. A mortgage made to HRAA’s subsidiary related to certain real estate which houses HRAA’s main offices in Plantation, Florida.  The loan originated in July 2010 in the amount of $192,500 and matures July 2020, when a balloon principal payment of approximately $129,000 becomes due.  The loan is collateralized by the real estate and is personally guaranteed by a stockholder of HRAA. Interest is fixed at 6.625% for the first five years of the loan, and converts to an adjustable rate for the second five years at the Federal Funds Rate plus 3.25%, as established by the United State Federal Reserve.  The balance under this mortgage loan as of June 30, 2013 was approximately $177,000. Monthly payments for principal and interest are approximately $1,500 until July 2015, when the total monthly payment may vary due to the adjustable interest rate provision in the note.

4. A factoring facility with a finance company whereby, under the terms of the agreement, the Company, at its discretion, assigns the collection rights of its receivables to the finance company in exchange for an advance rate of 85% of face value.  The assignments are transacted with recourse in the event of non-payment.   For the three months ended June 30, 2013, the Company had factored approximately $1,274,000 of receivables and had received cash advances of approximately $1,083,000. Outstanding receivables purchased by the factor as of June 30, 2013 were approximately $635,000 and included in accounts receivable in the accompanying unaudited condensed consolidated balance sheet, and the secured loan due to the lender was approximately $553,000. Factor fees in 2013 were approximately $69,000, and are included in interest expenses.

19

5. The Company leases certain office equipment under non-cancelable operating lease arrangements.  Monthly payments under the lease agreements are approximately $500 as of June 30, 2013.

6. During December 2012 and January 2013, the Company entered into a round of Loan Agreement and Promissory notes totaling $2,035,000. As of December 31, 2012, the Company had received $815,000.  The remainder of $1,220,000 was received in January and February 2013.

The Company’s merger yielded cash from the sale of common stock that was approximately $600,000 short of the expected amount to be raised in order in order to execute its growth plan for the near future.  Since the time of the Merger, the Company has transacted equity capital raises totaling approximately $1,060,000 of additional capital infusion.  The Company has continued its buildup of the personnel and business development efforts and has incurred operating losses.  As a result, the Company possesses a deficit in working capital of $684,681 at June 30, 2013 and continues to hold discussions with interested parties regarding additional investment in the Company’s common stock in amounts which approximate its current estimated working capital shortfall. Should efforts to raise additional capital prove to be unsuccessful; the Company will reduce its growth plans accordingly.

Going Concern

The Company’s future success is dependent upon its ability to achieve profitable operations and generate cash from operating activities, and upon additional financing, management believes they can raise the appropriate funds needed to support their business plan and develop an operating company which is cash flow positive.

However, as of June 30, 2013, the Company has an accumulated deficit and for the three and six months ended June 30, 2013, incurred net losses, and has used net cash in operations. The Company has not been able to generate sufficient cash from operating activities to fund its ongoing operations. There is no guarantee that the Company will be able to generate enough revenue and/or raise capital to support its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

2013 Outlook

Now that the deadline for the ICD-10 Transition is finalized for October 2014, many healthcare executives are asking, “How should we get back on track in order to mitigate our financial and compliance risk?”  In response to this question, HRAA developed the ICD Visualizer ™ . Utilizing knowledge from healthcare industry subject matter experts combined with exceptional insight into what providers really need, the ICD Visualizer ™   assists healthcare leaders with their need to understand the exponential impact of the transition to ICD-10 and how it relates to reimbursement risks, clinical documentation quality, coding productivity and process changes.

By utilizing a business intelligence platform known for its ease of use and visualization capabilities, ICD Visualizer ™  is designed as a multidimensional environment that enables chief financial officers, vice presidents of payer relations, revenue cycle directors, HIM directors, coders and clinicians to explore the impact ICD-10 will have across the enterprise and within both inpatient and outpatient services.  ICD Visualizer ™   contains a set of baseline analytics that quantify the impact across hospitals, service lines, departments and physicians.  Because ICD Visualizer ™   has customizable analytics, analysts and executives are able to explore their own data and visualize a unique representation of their financial and operational needs well beyond the ICD-9 to ICD-10 transition phase.

Another factor in the outlook for 2013 is the new Hospital Readmission Reduction Program, (HRRP), an Affordable Care Act provision, creates increasing financial penalties for hospitals with higher than expected adjusted readmissions within 30 days. The Centers for Medicare and Medicaid Services, (CMS) expect HRRP to help to control IPPS payment penalties to hospitals having higher than average readmissions within 30 days for 3 conditions: Acute Myocardial Infarction, (AMI), Heart Failure, (HF), and Pneumonia, (PN). The measures included in the policy represent high volume and high cost conditions and are endorsed by the National Quality Forum (NQF). The measures have some exclusion for readmissions that are unrelated to the prior discharge (such as planned admissions for scheduled procedures subsequent to AMI or transfers to another hospital).

In 2013, DRG payment rates will be reduced based on a hospital’s ratio of actual to expected readmissions. The reduction applies to the base DRG payment only and does not include IME, DSH or outlier payments. In FY 2013, the maximum payment reduction is 1 percent. In 2014, penalties double to 2% and cap at 3% in 2015. According to the CMS a total of 2,217 hospitals are expected to be penalized in the first year of the program. Of those hospitals, 307 will pay the maximum penalty at 1 percent of their regular Medicare reimbursements. The penalty cap will increase to two percent in 2014 and three percent in 2015 and new measures and metrics will be added.

Readmissions Visualizer ™  is a significant aspect of our value proposition for this factor. This business intelligence product is built on a premier business discovery platform that provides the ability to view current inpatient and historical readmission information through an intuitive Web interface for the purpose of decreasing readmissions within the healthcare system and to classify current census risk for readmission so care management can allocate appropriate resources.  Users can view current census including Reason for Admission, History of HF, AMI, PN, LACE Readmission Score, Emergency Room History, and more.

20

Readmissions Visualizer ™  also trends and analyzes performance for predictive models to plan enterprise resource budgeting, partner planning, resource allocation and workflow interventions for care management at transitions to improve care quality and continuity.

The company is poised to leverage these factors and more facing the healthcare industry through the sales of its products and solutions that allow healthcare organizations to view patient lifecycles horizontally as opposed to vertically thus reducing the cost of delivery and improving the delivery experience for Doctors, Nurses and Patients.

Off-Balance Sheet Arrangements

None.

Critical Accounting Policies

The preparation of unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires our management to make assumptions, estimates, and judgments that affect the amounts reported, including the notes thereto, and related disclosures of commitments and contingencies, if any. We have identified certain accounting policies that are significant to the preparation of our consolidated financial statements. These accounting policies are important for an understanding of our financial condition and results of operations. Critical accounting policies are those that are most important to the portrayal of our financial condition and results of operations and require management’s difficult, subjective, or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Certain accounting estimates are particularly sensitive because of their significance to financial statements and because of the possibility that future events affecting the estimate may differ significantly from management’s current judgments. We believe the following critical accounting policies involve the most significant estimates and judgments used in the preparation of our consolidated financial statements.

The Company is an emerging growth company; therefore we have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(2)(B) of the Jumpstart Our Business Startups Act. As a result of this election, our consolidated financial statements may not be comparable to companies that comply with public company effective dates.

Software

Costs incurred in connection with the development of software products are accounted for in accordance with the Financial Accounting Standards Board Accounting Standards Codification ("ASC") 985  Costs of Software to Be Sold, Leased or Marketed.”   Costs incurred prior to the establishment of technological feasibility are charged to research and development expense. Software development costs are capitalized after a product is determined to be technologically feasible and is in the process of being developed for market and capitalization ceases after the general release of the software. Amortization of capitalized software development costs begins upon initial product shipment after general release. Capitalized software development costs are amortized over the estimated life of the related product (generally thirty-six months) using the straight-line method. The Company evaluates its software assets for impairment whenever events or change in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of software assets to be held and used is measured by a comparison of the carrying amount of the asset to the future net undiscounted cash flows expected to be generated by the asset.  If such software assets are considered to be impaired, the impairment to be recognized is the excess of the carrying amount over the fair value of the software asset. 

Software maintenance costs are charged to expense as incurred. Expenditures for enhanced functionality are capitalized. The cost of the software and the related accumulated amortization are removed from the accounts upon retirement of the software with any resulting loss being recorded in operations.  No amortization expense was recorded in the accompanying unaudited consolidated financial statements as of June 30, 2013 since our first software product was released on July 15th.

Use of Estimates

Management uses estimates and assumptions in preparing financial statements.  Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses.  Actual results could differ from those estimates. Significant accounting estimates reflected in the Company’s consolidated financial statements include valuation of accounts receivable, valuation of property and equipment, valuation and amortization period of software, valuation of beneficial conversion features in convertible debt, valuation of equity based instruments issued for other than cash, revenue recognition, and the valuation allowance on deferred tax assets.

Revenue Recognition

The Company recognizes services revenue based on the proportional performance method of recognizing revenue.

A portion of the Company’s revenue is generated from medical coding audit services. Auditing revenue is invoiced in accordance with the contract, generally at three benchmark time periods which coincide with when specific, obligatory field work services have been rendered and completed, the value of this portion of the contract price has been predetermined and agreed upon, and the client has received benefit or value in the form of the independent identification of system weaknesses and risk analysis. Further, collectability is reasonably assured due to the existence of a fixed fee contract and the size and financial health of the Company’s clients. Below is a description of the general benchmarks and work phases associated with the Company’s audit services:

● Planning Phase - work commences prior to and as soon as the contract is signed and includes setting the audit scope, scheduling of the job, assignment of audit staff, understanding the client and their systems, determination of sample size and sampling methods to be employed, and other specific items as outlined in the contract. The planning phase includes the determination of deliverables as defined in the contract, generally consisting of a listing of errors, training and a final report. The Company generally invoices and recognizes 50% of the contract value at the completion of the Planning Phase. Although all of the contracts contain a clause making the first 50% of the engagement fee due and non-refundable at this point, the Company does not deem this initial fee to be recognized as deferred revenue under SAB 104 due to the extensive amount of work to be done prior to accepting the contract.

21

● Field Work Phase – is performed at the client location and generally lasts one week and encompasses actual testing of sample claims preselected in the Planning Phase. The auditor generally preloads the selected claims into the Company’s proprietary software and audits the claim records by reviewing actual medical records. The software assists the auditor in determining proper classifications and allows the auditor to compare the proper classification against what was filed in the submission made by the client to Medicare. Notes and comments are recorded and audit reports are generated. The Company generally invoices and recognizes 40% of the contract value at the completion of the Field Work Phase.

● Reporting Phase – includes a summary of audit findings, exit conference with clients, and any other specific deliverables as determined by the contract. The Company generally invoices and recognizes the remaining 10% of the contract value at the completion of the Report Phase.

A portion of the Company’s revenue is derived from consulting, training and coding services provided. Revenue from these revenue streams is recognized after services are performed based on the quoted and agreed upon fee contained in its contracts.

For our education products sold on a self-study standalone basis or in multiple element contracts which include training and the product and training are separable elements  (see below) revenue is recognized for the product upon passing of title which occurs once the end user is granted access to our online curriculum courses.

The Company intends a general release of its first software product in the second quarter of 2013.  Software sales on a standalone basis will be recognized upon delivery of the software when evidence of the purchase arrangement exists and the price is determinable, and when collectability is reasonably assured.

Arrangements with customers may involve multiple elements including software products, education products, training, software product maintenance, coding services, coding audit services and other consulting services. Training on education products will occur after the education product sale. Education products are sold and may be used as a self-study product, although most of our customers elect to purchase our training services and therefore most of our contracts to date are multiple element contracts including one price for the education product and related training. We allocate the selling price to each element as discussed below. Training and maintenance on software products will generally occur after the software product sale. Other services may occur before or after the product sales and may not relate to the products.  Revenue recognition for multiple element arrangement is as follows:

Each element is accounted for separately when each element has value to the customer on a standalone basis and there is Company specific objective evidence of selling price of each deliverable. For revenue arrangements with multiple deliverables, the Company allocates the total customer arrangement to the separate units of accounting based on their relative selling prices as determined by the price of the items when sold separately. Once the selling price is allocated, the revenue for each element is recognized using the general and specific criteria under GAAP as discussed above for elements sold in non-multiple element arrangements.  A delivered item or items that do not qualify as a separate unit of accounting within the arrangement are combined with the other applicable undelivered items within the arrangement. The allocation of arrangement consideration and the recognition of revenue is then determined for those combined deliverables as a single unit of accounting.  The Company has historically sold its services with established rates which it believes is Company specific objective evidence of selling price. For the new software products, management has established selling prices which qualifies as Company specific objective evidence of selling price. Generally all elements in multiple element arrangements with Company customers qualify as separate units of account for revenue recognition purposes.

22

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Smaller reporting companies are not required to provide the information required by this item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act that are designed to ensure that information required to be disclosed in our reports filed or submitted to the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms, and that information is accumulated and communicated to management, including the principal executive and financial officer as appropriate, to allow timely decisions regarding required disclosures. Our principal executive officer and principal financial officer evaluated the effectiveness of disclosure controls and procedures as of June 30, 2013, pursuant to Rule 13a-15(b) under the Exchange Act.  Based on that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were not effective to ensure that information required to be included in our periodic SEC filings is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms. We have concluded that our disclosure controls and procedures are not effective. We lack internal controls and procedures due in part to the Company’s lack of sufficient personnel with expertise in the area of SEC reporting, generally accepted accounting principles (GAAP) and tax accounting procedures, as well as our lack of sufficient financial resources to implement the policies and controls required pursuant to the Exchange act.  At this time, we also have insufficient segregation of duties among our accounting personnel. We began to take steps to address these matters as we have hired an internal control specialist to assist in the design, implementation, and test of adequate controls.

We have made pivotal progress to mitigate internal control weaknesses; however, we must still complete the process of design-specific control procedures and test their effectiveness, and maintaining sufficient personnel to implement these tasks before we can report that this weakness has been fully remediated. 

A system of controls, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the system of controls are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control over Financial Reporting

No changes were made to our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

23

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, the Company may become involved in litigation relating to claims arising out of its operations in the normal course of business. We are not involved in any pending legal proceeding or litigation and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties is subject, which would reasonably be likely to have a material adverse effect on the Company.

Item 1A. Risk Factors

Smaller reporting companies are not required to provide the information required by this item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On April 1, 2013, the Company issued 54,847 shares of its common stock, par value $0.001 (the “Common Stock”) as compensation to two employees for services rendered through June 30, 2013. The shares were valued at $0.40 per share based on recent cash sales by the Company or $21,939 which was expensed.

On May 19, 2013, the Company raised $250,000 through the issuance of 625,000 shares of Common Stock at a price per share of $0.40 per share.

On May 29, 2013 and June 21, 2013, the Company raised $50,000 and $300,000 through the issuance of 125,000 and 750,000 shares of Common Stock at a price of $0.40 per share.

The above issuances of shares are exempt from registration, pursuant to Section 4(2) of the Securities Act.  These securities qualified for exemption under Section 4(2) of the Securities Act since the issuance securities by us did not involve a public offering. The offering was not a “public offering” as defined in Section 4(2) due to the insubstantial number of persons involved in the deal, size of the offering, manner of the offering and number of securities offered. We did not undertake an offering in which we sold a high number of securities to a high number of investors. In addition, these stockholders had the necessary investment intent as required by Section 4(2) since they agreed to and received share certificates bearing a legend stating that such securities are restricted pursuant to Rule 144 of the Securities Act. This restriction ensures that these securities would not be immediately redistributed into the market and therefore not be part of a “public offering.” Based on an analysis of the above factors, we have met the requirements to qualify for exemption under Section 4(2) of the Securities Act for this transaction.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosure.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

Exhibit Number	Description
31.1	Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes - Oxley Act of 2002.
31.2	Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes - Oxley Act of 2002.
32.1*	Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002.
101.INS**	XBRL Instance Document
101.SCH**	XBRL Taxonomy Extension Schema Document
101.CAL**	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**	XBRL Taxonomy Extension Label Linkbase Document
101.PRE**	XBRL Taxonomy Extension Presentation Linkbase Document

* The certification attached as Exhibit 32.1 accompanying this Quarterly Report on Form 10-Q is being furnished and is not deemed filed with the Securities and Exchange Commission.

** Furnished herewith. XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

24

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	HEALTH REVENUE ASSURANCE HOLDINGS, INC.
Dated: August 9, 2013	By:	/s/ Andrea Clark
		Andrea Clark
		Chief Executive Officer (Duly Authorized and Principal Executive Officer)

Dated: August 9, 2013	By:	/s/ Evan McKeown
		Evan McKeown
		Chief Financial Officer (Duly Authorized,  Principal Financial Officer and Principal Accounting Officer)

25

EX-31.1

EXHIBIT 31.1

Certification of Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Andrea Clark, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Health Revenue Assurance Holdings, Inc. (the “Registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a13a-15(f) and 15d-15(f)) for the registrant. Although, to date, no internal control policies and procedures have been established as being more fully described in the Company’s annual Form 10-K, we understand that it is required that we:

a)     Design such disclosure controls and procedures or cause such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)     Design such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)     Evaluate the effectiveness of the registrant’s disclosure controls and procedures; and present in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d)     Disclose in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

6. As reported in our filing, there are significant deficiencies, including material weaknesses, in the design or operation of internal control over financial reporting. Although possible, we do not believe these weaknesses adversely affected the Company’s ability to initiate, authorize, record, process, and report financial data reliably in accordance with accounting principles generally accepted in the United States of America.

Date: August 9, 2013
	/s/ Andrea Clark
	Andrea Clark
	Chief Executive Officer (Principal Executive Officer)

EX-31.2

Exhibit 31.2

Certification of Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Evan McKeown, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Health Revenue Assurance Holdings, Inc. (the “Registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a13a-15(f) and 15d-15(f)) for the registrant. Although, to date, no internal control policies and procedures have been established as being more fully described in the Company’s annual Form 10-K, we understand that it is required that we:

a)     Design such disclosure controls and procedures or cause such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)     Design such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)     Evaluate the effectiveness of the registrant’s disclosure controls and procedures; and present in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d)     Disclose in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

6. As reported in our filing, there are significant deficiencies, including material weaknesses, in the design or operation of internal control over financial reporting. Although possible, we do not believe these weaknesses adversely affected the Company’s ability to initiate, authorize, record, process, and report financial data reliably in accordance with accounting principles generally accepted in the United States of America.

Date: August 9, 2013
	/s/ Evan McKeown
	Evan McKeown
	Chief Financial Officer (Principal Accounting Officer)

EX-32.1

EXHIBIT 32.1

CERTIFICATION

OF PRINCIPAL EXECUTIVE OFFICER AND

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U. S. C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Health Revenue Assurance Holdings, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2013 (the “Report”), I, Andrea Clark, Chief Executive Officer of the Company, and I, Andrea Clark, Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:

1.    The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

2.    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2013	/s/ Andrea Clark
	Andrea Clark
	Chief Executive Officer (Principal Executive Officer)

Date: August 9, 2013	/s/ Evan McKeown
	Evan McKeown
	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed from within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Subsequent Events

6 Months Ended

Jun. 30, 2013

Subsequent Events

SUBSEQUENT EVENTS

11 – SUBSEQUENT EVENTS

During July and August pursuant to private placements, the Company issued 1,000,000 shares of common stock for cash with a per share price of $0.40 per share or $ 400,000.

XML

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Statements of Operations [Abstract]
Revenues	$ 2,067,464	$ 1,028,266	$ 4,224,061	$ 1,634,096
Cost of Revenues	975,632	453,233	1,960,952	884,352
Gross Profit	1,091,832	575,033	2,263,109	749,744
Operating Expenses
Selling and administrative expenses (includes stock compensation of $70,048 and $0 in 2013 and 2012, respectively)	1,941,675	1,047,334	3,385,759	1,656,605
Research and development		20,920	289	53,133
Depreciation and amortization	19,169	12,879	44,598	22,750
Total Operating Expenses	1,960,844	1,081,133	3,430,646	1,732,488
Operating Loss	(869,012)	(506,100)	(1,167,537)	(982,744)
Other Income (Expense)
Other income, net	635		351
Interest expense	(228,684)	(4,922)	(364,702)	(10,842)
Total Other Income (Expense), net	(228,049)	(4,922)	(364,351)	(10,842)
Loss before provision for income taxes	(1,097,061)	(511,022)	(1,531,888)	(993,586)
Provision for income taxes
Net Loss	$ (1,097,061)	$ (511,022)	$ (1,531,888)	$ (993,586)
Net Loss Per Share
basic and diluted	$ (0.02)	$ (0.01)	$ (0.03)	$ (0.03)
Weighted Average Number of Shares Outstanding
basic and diluted	45,422,517	35,229,195	44,763,302	35,229,195

XML

Research and Developement and Software

6 Months Ended

Jun. 30, 2013

Research and Development and Software [Abstract]

RESEARCH AND DEVELOPMENT AND SOFTWARE

4 – RESEARCH AND DEVELOPMENT AND SOFTWARE

Early 2012, the Company started developing the Visualizer™ suite. This intuitive and easy to use business intelligence product is designed to meet the emerging need for healthcare analytics. Customer data is infused into the suite, and the Company uses this to develop pre-defined analytics targeted to address healthcare’s emerging concerns and needs.

HRAA’s Visualizer™ suite will encompass multiple offerings. The first project currently under development is ICD Visualizer™, which assists healthcare leaders with their need to understand the exponential impact of the transition to ICD-10 including work flow, productivity, process changes and documentation and reimbursement risks. The application helps to visualize the reimbursement and operational effects of transitioning organizations to ICD-10 and identify where to focus education and documentation issues. It enables clients to develop a custom work plan to mitigate risks from the highest areas of exposure to the least.

The transition to ICD-10 is causing a paradigm shift in healthcare. In response, we have developed a new product called OMC Initiator (Outsourced Medical Coding) for processing healthcare claims within hospitals. This product captures data from the physician or the hospital’s financial systems and correlates the data in a manner that expedites the processing of a claim. To validate our new product, our team of Emergency Department Coders (ED Coders) is continuously evaluating the process of coding claims in order to enhance our product.

At June 30, 2013, the Company had accumulated a total of $940,305 in capitalized costs related to the development of the Visualizer™ suite and the OMC Initiater which is included as Software on the accompanying consolidated balance sheet.

Amortization expense for software, for the three months ended June 30, 2013 and 2012 was $0, respectively as the Company has yet to have a general release of either product. Software consisted of the following at June 30, 2013 and December 31, 2012:

	June 30, 2013		December 31, 2012
Software	$	940,305	$	258,933
Accumulated amortization		-		-
Software, net	$	940,305	$	258,933

The following is a schedule of estimated future amortization expense of software at June 30, 2013 (assumes amortization begins July 15, 2013 and a three-year amortization period):

Estimated amortization expense of software is as follows:
July 1, 2013 through December 31, 2013	$	156,717
2014		313,435
2015		313,435
2016		156,718
TOTAL	$	940,305

XML

Summary of Significant Accounting Policies (Details)	6 Months Ended
	Jun. 30, 2013
Summary of significant accounting policies (Textual)
Percentage of contract value that is recognized at the completion of the planning phase	50.00%
Percentage of engagement fee due and non-refundable as per clause	50.00%
Percentage of contract value recognized at completion of field work phase	40.00%
Remaining percentage of contract value that recognize at completion of report phase	10.00%

XML

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2013

Summary of Significant Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.

Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (all of which are of a normal recurring nature) considered necessary for a fair presentation have been included. Operating results for the three months ended June 30, 2013 are not indicative of the results that may be expected for the year ending December 31, 2013 or for any other future period. These unaudited condensed consolidated financial statements and the unaudited notes thereto should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2013 (our “10-K”).

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Health Revenue Assurance Associates, Inc. and Dream Reachers, LLC. All significant inter-company transactions and balances are eliminated in consolidation.

Use of Estimates

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements.  Actual results could differ from those estimates. Significant accounting estimates reflected in the Company’s consolidated financial statements include valuation of accounts receivable, valuation of property and equipment, valuation and amortization period of software, valuation of beneficial conversion features in convertible debt, valuation of equity based instruments issued for other than cash, revenue recognition, and the valuation allowance on deferred tax assets.

Cash

Cash

For purposes of the statement of cash flows, the Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company’s cash balances are maintained at various banks that are insured by the Federal Deposit Insurance Corporation subject to certain limitations.

Accounts Receivable and Factoring

Accounts Receivable and Factoring

Accounts receivable are stated at the amounts management expects to collect.  An allowance for doubtful accounts is recorded using a specific identification method based on a combination of historical experience, aging analysis and information on specific accounts.  Account balances are written off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.  Management has determined that no allowance is required at June 30, 2013. The Company accounts for its factoring arrangements as either a sale or a secured financing based on the criteria in ASC 860 "Transfers and Servicing".  Estimates of allowances for doubtful accounts are reflected as a recourse obligation, a liability, for factor arrangements treated as a sale with recourse or as a contra asset accounts receivable allowance account for arrangements accounted for as a secured financing.

Software

Software

Costs incurred in connection with the development of software products are accounted for in accordance with the Financial Accounting Standards Board Accounting Standards Codification ("ASC") 985  Costs of Software to Be Sold, Leased or Marketed.”   Costs incurred prior to the establishment of technological feasibility are charged to research and development expense. Software development costs are capitalized after a product is determined to be technologically feasible and is in the process of being developed for market and capitalization ceases after the general release of the software. Amortization of capitalized software development costs begins upon initial product shipment after general release. Capitalized software development costs are amortized over the estimated life of the related product (generally thirty-six months) using the straight-line method. The Company evaluates its software assets for impairment whenever events or change in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of software assets to be held and used is measured by a comparison of the carrying amount of the asset to the future net undiscounted cash flows expected to be generated by the asset.  If such software assets are considered to be impaired, the impairment to be recognized is the excess of the carrying amount over the fair value of the software asset. 

Software maintenance costs are charged to expense as incurred. Expenditures for enhanced functionality are capitalized. The cost of the software and the related accumulated amortization are removed from the accounts upon retirement of the software with any resulting loss being recorded in operations.  No amortization expense was recorded in the accompanying unaudited consolidated financial statements as of June 30, 2013 since our first software product was released on July 15th.

Fair Value Measurements and Fair Value of Financial Instruments

Fair Value Measurements and Fair Value of Financial Instruments

Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques.  Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy:

● Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets;

● Level 2—Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities; and

● Level 3—Unobservable inputs that are supported by little or no market activity that is significant to the fair value of assets or liabilities.

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

Revenue Recognition

Revenue Recognition

The Company recognizes services revenue based on the proportional performance method of recognizing revenue.

A portion of the Company’s revenue is generated from medical coding audit services. Auditing revenue is invoiced in accordance with the contract, generally at three benchmark time periods which coincide with when specific, obligatory field work services have been rendered and completed, the value of this portion of the contract price has been predetermined and agreed upon, and the client has received benefit or value in the form of the independent identification of system weaknesses and risk analysis. Further, collectability is reasonably assured due to the existence of a fixed fee contract and the size and financial health of the Company’s clients. Below is a description of the general benchmarks and work phases associated with the Company’s audit services:

● Planning Phase - work commences prior to and as soon as the contract is signed and includes setting the audit scope, scheduling of the job, assignment of audit staff, understanding the client and their systems, determination of sample size and sampling methods to be employed, and other specific items as outlined in the contract. The planning phase includes the determination of deliverables as defined in the contract, generally consisting of a listing of errors, training and a final report. The Company generally invoices and recognizes 50% of the contract value at the completion of the Planning Phase. Although all of the contracts contain a clause making the first 50% of the engagement fee due and non-refundable at this point, the Company does not deem this initial fee to be recognized as deferred revenue under SAB 104 due to the extensive amount of work to be done prior to accepting the contract.

● Field Work Phase – is performed at the client location and generally lasts one week and encompasses actual testing of sample claims preselected in the Planning Phase. The auditor generally preloads the selected claims into the Company’s proprietary software and audits the claim records by reviewing actual medical records. The software assists the auditor in determining proper classifications and allows the auditor to compare the proper classification against what was filed in the submission made by the client to Medicare. Notes and comments are recorded and audit reports are generated. The Company generally invoices and recognizes 40% of the contract value at the completion of the Field Work Phase.

● Reporting Phase – includes a summary of audit findings, exit conference with clients, and any other specific deliverables as determined by the contract. The Company generally invoices and recognizes the remaining 10% of the contract value at the completion of the Report Phase. 

A portion of the Company’s revenue is derived from consulting, training and coding services provided. Revenue from these revenue streams is recognized after services are performed based on the quoted and agreed upon fee contained in its contracts.

For our education products sold on a self-study standalone basis or in multiple element contracts which include training and the product and training are separable elements  (see below) revenue is recognized for the product upon passing of title which occurs once the end user is granted access to our online curriculum courses.

On July 15th the Company issued a general release for one of its products Visualizer ™. Additional product releases are anticipated to be for general availability during the 4th quarter of 2013.  Software sales on a standalone basis will be recognized upon delivery of the software when evidence of the purchase arrangement exists and the price is determinable, and when collectability is reasonably assured.

Arrangements with customers may involve multiple elements including software products, education products, training, software product maintenance, coding services, coding audit services and other consulting services. Training on education products will occur after the education product sale. Education products are sold and may be used as a self-study product, although most of our customers elect to purchase our training services and therefore most of our contracts to date are multiple element contracts including one price for the education product and related training. We allocate the selling price to each element as discussed below. Training and maintenance on software products will generally occur after the software product sale. Other services may occur before or after the product sales and may not relate to the products.  Revenue recognition for multiple element arrangement is as follows:

Each element is accounted for separately when each element has value to the customer on a standalone basis and there is Company specific objective evidence of selling price of each deliverable. For revenue arrangements with multiple deliverables, the Company allocates the total customer arrangement to the separate units of accounting based on their relative selling prices as determined by the price of the items when sold separately. Once the selling price is allocated, the revenue for each element is recognized using the general and specific criteria under GAAP as discussed above for elements sold in non-multiple element arrangements. A delivered item or items that do not qualify as a separate unit of accounting within the arrangement are combined with the other applicable undelivered items within the arrangement. The allocation of arrangement consideration and the recognition of revenue is then determined for those combined deliverables as a single unit of accounting.  The Company has historically sold its services with established rates which it believes is Company specific objective evidence of selling price. For the new software products, management has established selling prices which qualifies as Company specific objective evidence of selling price. Generally all elements in multiple element arrangements with Company customers qualify as separate units of account for revenue recognition purposes.

Cost of Revenues

Cost of Revenues

Cost of revenues includes labor costs for services and education development costs. There were no depreciation or amortization costs in 2013 or 2012 that were allocable to cost of sales. In future periods, amortization of capitalized software costs will be included in costs of revenues.

Earnings Per Share

Earnings Per Share

The Company computes and presents earnings or losses per share in accordance with FASB ASC Topic 260, Earnings per share.  Basic earnings or losses per share are computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding.  Diluted earnings or loss per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares and common stock equivalents outstanding, calculated on the treasury stock method for options and warrants using the average market prices during the period.

As the Company incurred a net loss in all periods presented, all potentially dilutive securities were excluded from the computation of diluted loss per share since the effect of including them is anti-dilutive. There were no dilutive securities outstanding at June 30, 2013 and 2012 respectively

Recent Accounting Pronouncements

Recent Accounting Pronouncements

We have implemented all new accounting standards that are in effect and that may impact our unaudited condensed consolidated financial statements and do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our consolidated financial position or results of operations.

XML

Stockholders' Equity (Details) (USD $)	0 Months Ended					1 Months Ended			3 Months Ended	6 Months Ended
	Jun. 21, 2013	May 29, 2013	May 19, 2013	Apr. 01, 2013	Jan. 15, 2013	Mar. 31, 2013	Feb. 28, 2013	Jan. 31, 2013	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2012
Stockholders' Equity (Textual)
Common stock, gross proceeds	$ 300,000	$ 50,000	$ 250,000		$ 13,000					$ 618,000	$ 818,337
Common stock shares issued	750,000	125,000	625,000		46,429		5,575,000
Sale price of stock, per share	$ 0.40	$ 0.40	$ 0.40		$ 0.28			$ 0.49
Stock issuance expense								24,630
Stock issued for compensation, shares								50,266
Term of Agreement						1 year
Additional expense in connection with financing transaction									20,125
Prepaid expense in connection with financing transaction									57,021	57,021
Issuance of shares for cash						80,500
Issuance of shares for cash, shares						230,000
Issuance of stock for services to employees, shares				54,847
Issuance of stock for services to employees, amount				$ 21,939
Share price, per share				$ 0.40		$ 0.35

XML

Research and Developement and Software (Details) (Software [Member], USD $)	Jun. 30, 2013	Dec. 31, 2012
Software [Member]
Schedule of software's
Software	$ 940,305	$ 258,933
Accumulated amortization
Software, net	$ 940,305	$ 258,933

XML

Accounts Receivable (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Accounts Receivable (Textual)
Bad debt expense on trade accounts receivable			$ 6,450

XML

Factoring Agreement (Details) (USD $)	1 Months Ended	3 Months Ended	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2013	Dec. 31, 2012
Factoring Agreement (Textual)
Period of factoring agreement	1 year
Percentage of total receivable's face value exchanged under factoring agreement	85.00%
Aggregate amount under factoring agreement		$ 1,274,000
Advance received under factoring agreement		1,083,000
Outstanding receivables purchased by factor		635,000	635,000
Loan payable to factor		552,439	552,439	827,075
Factor fees			$ 31,000

XML

Subsequent Events (Details) (USD $)			1 Months Ended
	Apr. 01, 2013	Mar. 31, 2013	Aug. 09, 2013 Subsequent Event [Member]
Subsequent Events (Textual)
Stock issued during period			$ 400,000
Stock issued during period, shares			1,000,000
Share price, per share	$ 0.40	$ 0.35	$ 0.40

XML

Long Term Debt and Notes Payable (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Summary of Long Term debt
Total	$ 200,639	$ 218,970
Less current portion	(32,610)	(37,513)
Total long term portion	168,029	181,457
Bank term loan [Member]
Summary of Long Term debt
Total	23,229	38,897
Mortgage loan [Member]
Summary of Long Term debt
Total	$ 177,410	$ 180,073

XML

Accounts Receivable (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Summary of Accounts receivable
Accounts receivable	$ 1,510,690	$ 1,246,814
Allowance for doubtful accounts
Total	$ 1,510,690	$ 1,246,814

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Cash flows from Operating Activities:
Net loss	$ (1,531,888)	$ (993,586)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	44,598	22,750
Stock issued for compensation	70,048
Amortization of debt discount	209,915	2,198
Bad debt expense	6,450
Change in operating assets and liabilities:
Accounts receivable, net	(270,326)	(304,609)
Prepaid expenses	26,924	21,680
Other assets	(12,140)	(1,124)
Accounts payable	130,555	309,826
Unearned revenue		52,069
Accrued liabilities	239,414
Net Cash used in operating activities	(1,086,450)	(890,796)
Cash flows from Investing Activities:
Capitalization of internally developed software	(681,372)
Purchases of property and equipment	(7,732)	(21,175)
Net Cash used in investing activities	(689,104)	(21,175)
Cash flows from Financing Activities:
Borrowings (Repayments) on line of credit, net	(34,738)	51,500
Settlement payments	(92,222)
Loan proceeds	1,220,000
Loan proceeds from factor, net	(274,636)
Repayments of debt obligations	(383,125)	(17,629)
Issuance of stock for cash net of offering cost	618,000	818,337
Net Cash provided by financing activities	1,053,279	852,208
Net decrease in cash	(722,275)	(59,763)
Cash at beginning of period	893,458	198,500
Cash at ending of period	171,183	138,737
Supplemental schedule of cash paid during the period for:
Interest	295,950	14,898
Income Taxes
Supplemental schedule of non-cash investing and financing activities:
Issuance of stock to repay debt		563,907
Capital lease obligation incurred for use of equipment	28,701	38,704
Beneficial conversion feature on convertible debt charged to additional paid in capital		300,000
Shares issued as a loan fee	679,353
Financed Equipment purchases	54,105
Insurance premium finance contract recorded as prepaid asset	57,573
Prepaid common stock issued for services	$ 57,021

XML

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2013

Summary of Significant Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.

Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (all of which are of a normal recurring nature) considered necessary for a fair presentation have been included. Operating results for the three months ended June 30, 2013 are not indicative of the results that may be expected for the year ending December 31, 2013 or for any other future period. These unaudited condensed consolidated financial statements and the unaudited notes thereto should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2013 (our “10-K”).

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Health Revenue Assurance Associates, Inc. and Dream Reachers, LLC. All significant inter-company transactions and balances are eliminated in consolidation.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements.  Actual results could differ from those estimates. Significant accounting estimates reflected in the Company’s consolidated financial statements include valuation of accounts receivable, valuation of property and equipment, valuation and amortization period of software, valuation of beneficial conversion features in convertible debt, valuation of equity based instruments issued for other than cash, revenue recognition, and the valuation allowance on deferred tax assets.

Cash

For purposes of the statement of cash flows, the Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company’s cash balances are maintained at various banks that are insured by the Federal Deposit Insurance Corporation subject to certain limitations.

Accounts Receivable and Factoring

Accounts receivable are stated at the amounts management expects to collect.  An allowance for doubtful accounts is recorded using a specific identification method based on a combination of historical experience, aging analysis and information on specific accounts.  Account balances are written off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.  Management has determined that no allowance is required at June 30, 2013. The Company accounts for its factoring arrangements as either a sale or a secured financing based on the criteria in ASC 860 "Transfers and Servicing".  Estimates of allowances for doubtful accounts are reflected as a recourse obligation, a liability, for factor arrangements treated as a sale with recourse or as a contra asset accounts receivable allowance account for arrangements accounted for as a secured financing.

Software

Costs incurred in connection with the development of software products are accounted for in accordance with the Financial Accounting Standards Board Accounting Standards Codification ("ASC") 985  Costs of Software to Be Sold, Leased or Marketed.”   Costs incurred prior to the establishment of technological feasibility are charged to research and development expense. Software development costs are capitalized after a product is determined to be technologically feasible and is in the process of being developed for market and capitalization ceases after the general release of the software. Amortization of capitalized software development costs begins upon initial product shipment after general release. Capitalized software development costs are amortized over the estimated life of the related product (generally thirty-six months) using the straight-line method. The Company evaluates its software assets for impairment whenever events or change in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of software assets to be held and used is measured by a comparison of the carrying amount of the asset to the future net undiscounted cash flows expected to be generated by the asset.  If such software assets are considered to be impaired, the impairment to be recognized is the excess of the carrying amount over the fair value of the software asset. 

Software maintenance costs are charged to expense as incurred. Expenditures for enhanced functionality are capitalized. The cost of the software and the related accumulated amortization are removed from the accounts upon retirement of the software with any resulting loss being recorded in operations.  No amortization expense was recorded in the accompanying unaudited consolidated financial statements as of June 30, 2013 since our first software product was released on July 15th.

Fair Value Measurements and Fair Value of Financial Instruments

Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques.  Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy:

● Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets;

● Level 2—Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities; and

● Level 3—Unobservable inputs that are supported by little or no market activity that is significant to the fair value of assets or liabilities.

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

Revenue Recognition

The Company recognizes services revenue based on the proportional performance method of recognizing revenue.

A portion of the Company’s revenue is generated from medical coding audit services. Auditing revenue is invoiced in accordance with the contract, generally at three benchmark time periods which coincide with when specific, obligatory field work services have been rendered and completed, the value of this portion of the contract price has been predetermined and agreed upon, and the client has received benefit or value in the form of the independent identification of system weaknesses and risk analysis. Further, collectability is reasonably assured due to the existence of a fixed fee contract and the size and financial health of the Company’s clients. Below is a description of the general benchmarks and work phases associated with the Company’s audit services:

● Planning Phase - work commences prior to and as soon as the contract is signed and includes setting the audit scope, scheduling of the job, assignment of audit staff, understanding the client and their systems, determination of sample size and sampling methods to be employed, and other specific items as outlined in the contract. The planning phase includes the determination of deliverables as defined in the contract, generally consisting of a listing of errors, training and a final report. The Company generally invoices and recognizes 50% of the contract value at the completion of the Planning Phase. Although all of the contracts contain a clause making the first 50% of the engagement fee due and non-refundable at this point, the Company does not deem this initial fee to be recognized as deferred revenue under SAB 104 due to the extensive amount of work to be done prior to accepting the contract.

● Field Work Phase – is performed at the client location and generally lasts one week and encompasses actual testing of sample claims preselected in the Planning Phase. The auditor generally preloads the selected claims into the Company’s proprietary software and audits the claim records by reviewing actual medical records. The software assists the auditor in determining proper classifications and allows the auditor to compare the proper classification against what was filed in the submission made by the client to Medicare. Notes and comments are recorded and audit reports are generated. The Company generally invoices and recognizes 40% of the contract value at the completion of the Field Work Phase.

● Reporting Phase – includes a summary of audit findings, exit conference with clients, and any other specific deliverables as determined by the contract. The Company generally invoices and recognizes the remaining 10% of the contract value at the completion of the Report Phase. 

A portion of the Company’s revenue is derived from consulting, training and coding services provided. Revenue from these revenue streams is recognized after services are performed based on the quoted and agreed upon fee contained in its contracts.

For our education products sold on a self-study standalone basis or in multiple element contracts which include training and the product and training are separable elements  (see below) revenue is recognized for the product upon passing of title which occurs once the end user is granted access to our online curriculum courses.

On July 15th the Company issued a general release for one of its products Visualizer ™. Additional product releases are anticipated to be for general availability during the 4th quarter of 2013.  Software sales on a standalone basis will be recognized upon delivery of the software when evidence of the purchase arrangement exists and the price is determinable, and when collectability is reasonably assured.

Arrangements with customers may involve multiple elements including software products, education products, training, software product maintenance, coding services, coding audit services and other consulting services. Training on education products will occur after the education product sale. Education products are sold and may be used as a self-study product, although most of our customers elect to purchase our training services and therefore most of our contracts to date are multiple element contracts including one price for the education product and related training. We allocate the selling price to each element as discussed below. Training and maintenance on software products will generally occur after the software product sale. Other services may occur before or after the product sales and may not relate to the products.  Revenue recognition for multiple element arrangement is as follows:

Each element is accounted for separately when each element has value to the customer on a standalone basis and there is Company specific objective evidence of selling price of each deliverable. For revenue arrangements with multiple deliverables, the Company allocates the total customer arrangement to the separate units of accounting based on their relative selling prices as determined by the price of the items when sold separately. Once the selling price is allocated, the revenue for each element is recognized using the general and specific criteria under GAAP as discussed above for elements sold in non-multiple element arrangements. A delivered item or items that do not qualify as a separate unit of accounting within the arrangement are combined with the other applicable undelivered items within the arrangement. The allocation of arrangement consideration and the recognition of revenue is then determined for those combined deliverables as a single unit of accounting.  The Company has historically sold its services with established rates which it believes is Company specific objective evidence of selling price. For the new software products, management has established selling prices which qualifies as Company specific objective evidence of selling price. Generally all elements in multiple element arrangements with Company customers qualify as separate units of account for revenue recognition purposes.

Cost of Revenues

Cost of revenues includes labor costs for services and education development costs. There were no depreciation or amortization costs in 2013 or 2012 that were allocable to cost of sales. In future periods, amortization of capitalized software costs will be included in costs of revenues.

Earnings Per Share

The Company computes and presents earnings or losses per share in accordance with FASB ASC Topic 260, Earnings per share.  Basic earnings or losses per share are computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding.  Diluted earnings or loss per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares and common stock equivalents outstanding, calculated on the treasury stock method for options and warrants using the average market prices during the period.

As the Company incurred a net loss in all periods presented, all potentially dilutive securities were excluded from the computation of diluted loss per share since the effect of including them is anti-dilutive. There were no dilutive securities outstanding at June 30, 2013 and 2012 respectively.

Recent Accounting Pronouncements

We have implemented all new accounting standards that are in effect and that may impact our unaudited condensed consolidated financial statements and do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our consolidated financial position or results of operations.

XML

Lines of Credit

6 Months Ended

Jun. 30, 2013

Lines Of Credit [Abstract]

LINES OF CREDIT

5 – LINES OF CREDIT

Bank

The Company has a $150,000 revolving line of credit with a bank, effective in December 2008, for its general working capital needs. The line of credit is secured by all business assets, collateral, and personal guarantees. The line of credit has a maturity date of December 18, 2018. The interest rate per year is equal to the Bank’s Prime Rate plus 6.50 percent. The Bank’s prime rate of interest at June 30, 2013 was 3.25%. The balance due at June 30, 2013 was $137,500 with $25,863 reflected as a current portion. The first of seventy-two payments of $3,255 initiated January 18, 2013 and will continue through 2018.

Dell

The Company maintains a Dell Business Credit line of up to $50,000.  Interest rates vary under the line based on difference types of payment plans.  The balance due under the line as of June 30, 2013 was $48,928, which is included in line of credit, current portion in the accompanying unaudited condensed consolidated financial statements.

XML

Accounts Receivable

6 Months Ended

Jun. 30, 2013

Accounts Receivable [Abstract]

ACCOUNTS RECEIVABLE

3 - ACCOUNTS RECEIVABLE

Accounts receivable at June 30, 2013 and December 31, 2012 was as follows:

	June 30,		December 31,
	2013		2012
Accounts receivable	$	1,510,690	$	1,246,814
Allowance for doubtful accounts		-		-
Total	$	1,510,690	$	1,246,814

We had $6,450 and $0 in bad debt expense on trade accounts receivable for six months ended June 30, 2013 and 2012, respectively. (See Note 8)

XML

Research and Developement and Software (Details 1) (Computer Software, Intangible Asset [Member], USD $)	Jun. 30, 2013	Dec. 31, 2012
Computer Software, Intangible Asset [Member]
Schedule of estimated future amortization expense of software
July 1, 2013 through December 31, 2013	$ 156,717
2014	313,435
2015	313,435
2016	156,718
Software, net	$ 940,305	$ 258,933

XML

Long Term Debt and Notes Payable (Details 1) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Summary of notes payable
Principal amount of notes payable	$ 1,670,204
Unamortized discount	(808,131)
Notes payable, net of discount	862,073
Less current portion	(574,718)	(202,557)
Total long term portion	$ 287,355	$ 273,751

XML

Commitments and Contingencies (Details Textual) (USD $)	1 Months Ended
	Sep. 30, 2012	Jul. 31, 2012 Lawsuit	Sep. 30, 2011	Jun. 30, 2013	Dec. 31, 2012
Commitments and Contingencies (Textual)
Lease arrangements periodic payment per month	$ 500
Lease arrangement payment paid per month	5,008
Lease expiration term	5 years		1 year
Lease arrangements term, Description			One year with five successive one year renewal options.
Renewed period of lease arrangements	1 year
Increment percentage in lease rent payment on renewal	4.00%
Amortization of assets held under capital leases				20,500
Number of pending lawsuits resolved		2
Lawsuit settlement, amount payable		232,500
Terms of payment to Siddel for settlement of lawsuits		Eleven (11) payments totaling $232,500 pursuant to the terms of prior employment agreement.
Number of shares agreed to be transferred to company officer		3,299,802
Grace period for due payments under Settlement Agreement		7 days
Settlement Payable				23,056	115,278
Due to officer as stated in February 2012 merger agreement				$ 75,000	$ 75,000

XML

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Balance Sheets [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	46,511,409	39,054,867
Common stock, shares outstanding	46,511,409	39,054,867

XML

Commitments and Contingencies

6 Months Ended

Jun. 30, 2013

Commitments and Contingencies [Abstract]

COMMITMENTS AND CONTINGENCIES

8 – COMMITMENTS AND CONTINGENCIES

Commitments

Leases:

In September 2012, the Company started a non-cancelable operating lease for office equipment.  The lease term is 5 years. Lease payments during the five years are approximately $500 per month.

On September 1, 2011, the Company entered into a commercial lease agreement for additional office space.  The lease term is one year with five successive one year renewal options. Starting September 1, 2012, the lease has been renewed for one year with a fixed payment of approximately $5,008 per month. For each year thereafter of the initial year, the rent will be subject to an increment of 4%.

Capital Leases:

The Company leases its property and equipment from Dell Financial Services L.L.C. under a capital lease. The economic substance of the lease is that the Company is financing the acquisition of the assets through the lease and accordingly, it is recorded in the Company’s assets and liabilities.

The following is an analysis of the leased assets included in Property and Equipment:

	June 30, 2013
Equipment		70,670
Less accumulated depreciation		(20,405	)
Total	$	50,265

The lease agreement contains a bargain purchase option at the end of the lease term.

The following is a schedule by years of future minimum payments required under the lease together with their present value as of June 30, 2013:

Year Ending December 31:
2013	$	14,353
2014		28,706
2015		18,467
2016		983

Total minimum lease payments		62,509
Less amount representing interest		(9,972	)
Present value of minimum lease payments	$	52,537

Amortization of assets held under capital leases is included with depreciation expense and is approximately $20,500 as of June 30, 2013.

Settlement Agreement:

On May 8, 2012, the Company terminated the employment of our Chief Marketing Officer (“CMO”) and subsequently amended its complaint to enforce certain non-competition clauses contained in the employment agreement. The Company sought a declaration of its obligations to pay severance under the terms of its then-existing employment agreement with the CMO.

On July 9, 2012, the Company and the former CMO entered into a Settlement Agreement to resolve two pending lawsuits arising out of the termination of his employment agreement. The lawsuit was initiated by the Company against the former CMO in the United States District Court for the Southern District of Florida.  In addition, the former CMO sued the Company in the United States District Court of the District of Colorado.

Pursuant to the Settlement Agreement, the former CMO agreed to abolish all claims and lawsuits against the Company and its CEO and COO and resigned any and all positions which he had or presently may have had with the Company. As part of the Settlement Agreement, the Company agreed to make eleven (11) payments totaling $232,500 pursuant to the terms of his prior employment agreement. Additionally, the CMO agreed to transfer his 3,299,802 shares to an officer of the Company in 2012. These payments commenced July 2012, and the outstanding balance as of June 30, 2013 was $23,056. In addition, the Company has agreed to abolish all claims and lawsuits against the former CMO.  The Settlement Agreement has a seven (7) day grace period for payments to the former CMO, after which time, he may seek court intervention to enforce the payments.  The Company's Chief Executive Officer and Chief Operating Officer, respectively, have personally guaranteed the payments of the Settlement Agreement. As a result of the Settlement Agreement, both parties are dismissing their respective filings and have agreed to not enter any more lawsuits concerning the scope of this matter. The remaining balance due is included in the accompanying balance sheets as settlement payable.

Employment Agreements:

From time to time, the Company enters into employment agreements with certain of its employees.  These agreements typically include bonuses, some of which are performance-based in nature. As of June 30, 2013, no performance bonuses have been earned. The Company owes its CEO $75,000 as stated in the February 2012 merger agreement, which is accrued in the accompanying unaudited condensed consolidated Financial Statements as Due to officer.

Contingencies

From time to time, the Company is involved in litigation matters relating to claims arising from the ordinary course of business. While the results of such claims and legal actions cannot be predicted with certainty, the Company’s management does not believe that there are claims or actions, pending or threatened against the Company, the ultimate disposition of which would have a material adverse effect on our business, results of operations, financial condition or cash flows.

XML

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Statements of Operations [Abstract]
Stock compensation included in selling and administrative expenses	$ 70,048	$ 0	$ 70,048

XML

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2013	Dec. 31, 2012
Assets
Cash	$ 171,183	$ 893,458
Accounts receivable	1,510,690	1,246,814
Prepaid expenses	91,270	3,600
Other current assets	12,831	688
Total Current Assets	1,785,974	2,144,560
Property and Equipment, net	411,120	365,017
Software	940,305	258,933
Other assets	8,865	8,871
Finance costs, net	2,313	2,477
Total Other Assets	951,483	270,281
Total Assets	3,148,577	2,779,858
Liabilities and Stockholders' Equity
Accounts payable	338,296	207,741
Due to officer	75,000	75,000
Accrued expenses	136,152	64,077
Accrued payroll	641,621	412,186
Loan payable to factor	552,439	827,075
Accrued interest		4,524
Line of credit, current portion	74,791	25,000
Capital Leases, current portion	21,972	16,923
Notes payable, current portion, net of discount	574,718	202,557
Long term debt, current portion	32,610	37,513
Settlement Payable	23,056	115,278
Total Current Liabilities	2,470,655	1,987,874
Capital Leases (net of current portion)	30,565	23,974
Line of credit (net of current portion)	111,637	125,000
Notes payable (net of current portion), net of discount	287,355	273,751
Long term debt (net of current portion)	168,029	181,457
Total Liabilities	3,068,241	2,592,056
Commitments and Contingencies (see Note 8)
Stockholders' Equity:
Common stock ($0.001 par value, 75,000,000 shares authorized, 46,511,409 shares and 39,054,867 issued and outstanding at June 30, 2013 and December 31, 2012, respectively)	46,511	39,055
Additional paid-in capital	4,150,511	2,738,545
Subscription receivable		(5,000)
Accumulated deficit	(4,116,686)	(2,584,798)
Total Stockholders' Equity	80,336	187,802
Total Liabilities and Stockholders' Equity	$ 3,148,577	$ 2,779,858

XML

Research and Developement and Software (Details Textual) (Software [Member], USD $)	3 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Software [Member]
Research and Development and Software (Textual)
Accumulated capitalized cost	$ 940,305
Software amortization expense	$ 0	$ 0
Software future amortization period	3 years

XML

Nature of Business and Going Concern (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Nature of Business and Going Concern (Textual)
Cash	$ 171,183	$ 893,458

XML

Concentrations (Details)	3 Months Ended		6 Months Ended	12 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2013 Hospital	Jun. 30, 2013 Sales Revenue, Net [Member] Customer [Member] Customer	Jun. 30, 2013 Accounts Payable [Member] Vendor [Member] Vendor	Dec. 31, 2012 Accounts Payable [Member] Vendor [Member] Vendor	Jun. 30, 2013 Accounts Receivable [Member] Customer [Member] Customer	Dec. 31, 2012 Accounts Receivable [Member] Customer [Member] Customer
Concentrations (Textual)
Number of major customer		4			2	2
Number of major vendors			2	3
Concentration risk, percentage		66.00%	59.00%	68.00%	41.00%	62.00%
Number of hospitals	13
Percentage of sales generated by 13 hospitals	49.00%

XML

Commitments and Contingencies (Details) (USD $)	Jun. 30, 2013
Analysis of the leased assets included in property and equipment
Equipment	$ 70,670
Less accumulated depreciation	(20,405)
Total	$ 50,265

XML

Commitments and Contingencies (Details 1) (USD $)	Jun. 30, 2013
Schedule of future minimum payments required under lease
2013	$ 14,353
2014	28,706
2015	18,467
2016	983
Total minimum lease payments	62,509
Less amount representing interest	(9,972)
Present value of minimum lease payments	$ 52,537

XML

Factoring Agreement

6 Months Ended

Jun. 30, 2013

Factoring Agreement [Abstract]

FACTORING AGREEMENT

7 – FACTORING AGREEMENT

In June 2012, the Company entered into a one-year factoring agreement with a finance company.  The agreement automatically renews annually unless terminated by either party. Under the terms of the agreement, the Company, at its discretion, assigns the collection rights of its receivables to the finance company in exchange for an advance rate of 85% of face value.  The assignments are transacted with recourse only at the option of the finance company in the event of non-payment.  The Company's obligations under the factor agreement are secured by substantially all assets of the Company.  In accordance with ASC 860 "Transfers and Servicing" regarding transfers of receivables with recourse, this factoring arrangement is accounted for as a secured financing. For the three months ended June 30, 2013, the Company had factored approximately $1,274,000 of receivables and had received cash advances of approximately $1,083,000. Outstanding receivables purchased by the factor as of June 30, 2013 were approximately $635,000 and are included in accounts receivable in the accompanying unaudited condensed consolidated balance sheet, and the secured loan due to the lender was approximately $552,500. Factor fees for the three months ending June 30, 2013 were approximately $31,000, and are included in interest expenses. (See Note 3)

XML

Lines of Credit (Details) (USD $)			6 Months Ended
	Jun. 30, 2013	Dec. 31, 2012	Jun. 30, 2013 Revolving Credit Facility [Member] Payment	Jun. 30, 2013 Dell Business Credit Line [Member]
Lines of Credit (Textual)
Line of credit facility, maximum borrowing capacity			$ 150,000	$ 50,000
Line of credit maturity date			Dec. 18, 2018
Rate of interest above prime rate			6.50%
Prime rate of interest			3.25%
Outstanding balance			137,500
Revolving line of credit with a bank	74,791	25,000	25,863	48,928
Number of payments due			72
Revolving line of credit, periodic payment due amount			$ 3,255

XML

Concentrations

6 Months Ended

Jun. 30, 2013

Concentrations [Abstract]

CONCENTRATIONS

10 – CONCENTRATIONS

Sales to thirteen hospitals represented approximately 49% of net sales for the three months ended June 30, 2013. Wherein, seven and six hospitals respectively are part of two larger health systems.  The company has direct relationships with both the individual hospitals and the health systems.  As such, the strength of the relationship is driven by the individual hospitals.

Sales to four customers were approximately 66% of revenue for the three months ended June 30, 2013.

Two and three vendors represented approximately 59% and 68% of the outstanding accounts payable balance as of June 30, 2013 and December 31, 2012, respectively.

Two customers represented approximately 41% and 62% of the accounts receivable as of June 30, 2013 and December 31, 2012 respectively.

XML

Long Term Debt and Notes Payable

6 Months Ended

Jun. 30, 2013

Long Term Debt and Notes Payable [Abstract]

LONG TERM DEBT AND NOTES PAYABLE

6 – LONG TERM DEBT AND NOTES PAYABLE

Long Term debt:

Long Term debt consisted of the following at June 30, 2013:

	June 30, 2013		December 31, 2012
Bank term loan	$	23,229	$	38,897
Mortgage loan		177,410		180,073
		200,639		218,970
Less current portion		(32,610)		(37,513	)
Total long term portion	$	168,029	$	181,457

The Company has a term loan with a bank whose proceeds were used for general working capital needs (the “Term Loan”).  The Term Loan was established in March 2009 as a result of a conversion of a revolving line of credit.  The Term Loan is personally guaranteed by one of the Company’s stockholders and is collateralized by the assets of the Company.  Payments of principal and interest are approximately $2,700 per month. The Term Loan matures in five years and incurs interest at the rate of 6.75% per annum.  Balance due as of June 30, 2013 was approximately $25,500 and is included in the long term debt, current portion line item in the accompanying unaudited condensed consolidated balance sheet.

The Company has a mortgage related to certain real estate which houses the Company’s main offices in Plantation, Florida.  The loan originated July, 2010 in the amount of $192,500 and matures July 2020, when a balloon principal payment of approximately $129,000 becomes due.  The loan is collateralized by the real estate and is personally guaranteed by a principal stockholder of the Company. Interest is fixed at 6.625% for the first five years of the loan, and converts to an adjustable rate for the second five years at the Federal Funds Rate plus 3.25%, as established by the United State Federal Reserve. The balance under this mortgage loan as of June 30, 2013 was approximately $177,500 and is allocated to the current and long term debt line items in the accompanying unaudited condensed consolidated balance sheet. Monthly payments for principal and interest are approximately $1,500 until July 2015, when the total monthly payment may vary due to the adjustable interest rate provision in the note.

Notes payable:

In December 2012, the Company entered into loan agreements with various investors and issued promissory notes upon receipt of $815,000. The loan agreements have an interest rate of 12% per annum.  Principal and interest is payable over 26 months. Additionally, in connection with the financing, the Company issued 2,375,000 shares of common stock to the lenders as loan fees. The fair value per share of $0.28 (based on recent cash sales prices) was used to compute the relative fair value of the shares in accordance with ASC 470-20 which totaled $343,500 which was recorded as a debt discount with a credit to additional paid-in-capital and such discount is being amortized over the term of the loans. The unamortized discount was $259,423 as of June 30, 2013.

In January and February 2013, the Company entered into loan agreements with various investors and issued promissory notes upon receipt of $1,220,000. The loan agreements have an interest rate of 12% per annum.  Principal and interest is payable over 26 months. Additionally, in connection with the financing, the Company issued 5,575,000 shares of common stock to the lenders as loan fees (See note 9). The fair value per share of $0.28 (based on recent cash sales prices) was used to compute the relative fair value of the shares in accordance with ASC 470-20 which totaled approximately $679,500 which was recorded as a debt discount with a credit to additional paid-in-capital and such discount is being amortized over the term of the loans. The unamortized discount was $548,708 as of June 30, 2013.

The Company began paying principal and interest on the above mentioned notes in early 2013 in accordance with the payment terms.

Notes payable consisted of the following at June 30, 2013:

	June 30, 2013
Principal amount of notes payable	$	1,670,204
Unamortized discount		(808,131	)
Notes payable, net of discount		862,073
Less current portion		(574,718	)
Total Long term portion	$	287,355

XML

Nature of Business and Going Concern

6 Months Ended

Jun. 30, 2013

Nature of Business and Going Concern [Abstract]

NATURE OF BUSINESS AND GOING CONCERN

1 – NATURE OF BUSINESS AND GOING CONCERN

Overview

Health Revenue Assurance Holdings, Inc. (the “Company”) is a trusted source of timely, accurate and critical resources, technology and information that supports the performance of revenue integrity in assuring the existence of healthcare organizations. The Company and its subsidiaries’ products and services include business intelligence technology solutions, contract coding, billing, coding and compliance audits, education, revenue cycle consulting, physician services and ICD-10 transition services. The Company provides customized solutions to its clients with the highest regard for ethical standards and responsibility.

Dream Reachers, LLC, owns the Company’s offices and is the borrower on a mortgage loan related to such offices. Dream Reachers, LLC does not engage in real estate rental business. Its offices are occupied by Health Revenue Assurance Associates, Inc. (“HRAA”) at no cost and HRAA pays the related mortgage’s principal and interest, taxes and maintenance. The Company’s subsidiary HRAA is the sole member effective May 2011. Dream Reachers has been treated as a Subsidiary for accounting purposes in the Company’s unaudited condensed consolidated financial statements for all periods presented. (see Note 2)

Going Concern

The Company’s future success is dependent upon its ability to achieve profitable operations and generate cash from operating activities, and upon additional financing, Management believes they can raise the appropriate funds needed to support their business plan and develop an operating company which is cash flow positive.

However, as of June 30, 2013, the Company has an accumulated deficit and for the three and six months ended June 30, 2013, incurred net losses, and has used net cash in operations. The Company has not been able to generate sufficient cash from operating activities to fund its ongoing operations. There is no guarantee that the Company will be able to generate enough revenue and/or raise capital to support its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability or classification of recorded assets and liabilities that might result should the Company be unable to continue as a going concern.

As of June 30, 2013 the Company has a cash balance of approximately $171,000. The Company is currently addressing the going concern and liquidity issues. The Company expects an increase in cash flow as the result of a growing customer demand for medical billing, IT consulting, training, education and software products and services. In addition, the Company is evaluating financing opportunities through either equity or debt financing or a combination of both. 

XML

Long Term Debt and Notes Payable (Details Textual) (USD $)	1 Months Ended	6 Months Ended			1 Months Ended	2 Months Ended
	Jul. 31, 2010	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013 Term Loan [Member]	Dec. 31, 2012 Loan Agreements [Member]	Feb. 28, 2013 Loan Agreements [Member]
Long Term Debt and Notes Payable (Textual)
Payments of principal and interest (Monthly)				$ 2,700
Maturity period of term loan				5 years
Debt interest rate				6.75%	12.00%	12.00%
Term loan, balances due				25,500
Principal amount of notes payable		1,670,204
Received promissory note		862,073			815,000	1,220,000
Shares issued as a loan fee		679,353			343,500	679,500
Stock issued to lenders in lieu of loan fees					2,375,000	5,575,000
Fair value of stock					$ 0.28	$ 0.28
Principal and interest payable period					26 months	26 months
Unamortized discount as of June 30, 2013					259,423	548,708
Mortgage loan, face amount related to certain real estate	192,500
Mortgage loans on real estate, Maturity Date	Jul. 31, 2020
Balloon principal payment	129,000
Mortgage loan fixed interest rate	6.625%
Maturity loan related to certain real estate Interest rate description	Interest is fixed at 6.625% for the first five years of the loan, and converts to an adjustable rate for the second five years at the Federal Funds Rate plus 3.25%, as established by the United State Federal Reserve.
Balance under mortgage loan		177,500
Mortgage loans on real estate periodic payment (Monthly)	$ 1,500

XML

Accounts Receivable (Tables)

6 Months Ended

Jun. 30, 2013

Accounts Receivable [Abstract]

Summary of Accounts receivable

	June 30,		December 31,
	2013		2012
Accounts receivable	$	1,510,690	$	1,246,814
Allowance for doubtful accounts		-		-
Total	$	1,510,690	$	1,246,814

XML

Stockholders' Equity

6 Months Ended

Jun. 30, 2013

Stockholders' Equity [Abstract]

STOCKHOLDERS' EQUITY

9 – STOCKHOLDERS' EQUITY

Common Stock

On January 15, 2013, the company raised $13,000 through the issuance of 46,429 shares of common stock at a price per share of $0.28 per share.

On January 31, 2013, the company issued 50,266 shares of common stock as compensation to an employee for services rendered through March 31, 2013. The shares were valued at $0.49 per share based on the quoted trading price per share or $24,630 which was expensed.

On February 2013, the Company issued 5,575,000 shares of common stock in connection with a financing transaction as more fully described in note 6.

On March 2013, the Company entered into a one-year agreement with a consultant for 230,000 vested shares and cash consideration.  The shares were valued on the agreement date which was the measurement date at $0.35, based on the quoted trading price and the $80,500 is being expensed over the term of the contract.  The shares were issued on April 4, 2013 to the consultant. During the three months ending June 30, 2013, the company expensed and additional $20,125 and recorded $57,021 as prepaid expense in connection with this transaction.

On April 1, 2013, the company issued 54,847 shares of common stock as compensation to two employees for services rendered through June 30, 2013. The shares were valued at $0.40 per share based on recent cash sales by the Company or $21,939 which was expensed.

On May 19, 2013, the Company raised $250,000 through the issuance of 625,000 shares of common stock at a price per share of $0.40 per share.

On May 29, 2013 and June 21, 2013, the Company raised $50,000 and $300,000 through the issuance of 125,000 and 750,000 shares of common stock at a price of $0.40 per share.

XML

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2013

Commitments and Contingencies [Abstract]

Analysis of the leased assets included in Property and Equipment

	June 30, 2013
Equipment		70,670
Less accumulated depreciation		(20,405	)
Total	$	50,265

Schedule by years of future minimum payments required under the lease

Year Ending December 31:
2013	$	14,353
2014		28,706
2015		18,467
2016		983

Total minimum lease payments		62,509
Less amount representing interest		(9,972	)
Present value of minimum lease payments	$	52,537

XML

Research and Developement and Software (Tables)

6 Months Ended

Jun. 30, 2013

Research and Development and Software [Abstract]

Schedule of software's

	June 30, 2013		December 31, 2012
Software	$	940,305	$	258,933
Accumulated amortization		-		-
Software, net	$	940,305	$	258,933

Schedule of estimated future amortization expense of software

July 1, 2013 through December 31, 2013	$	156,717
2014		313,435
2015		313,435
2016		156,718
TOTAL	$	940,305

XML

Document and Entity Information	6 Months Ended
	Jun. 30, 2013	Aug. 07, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	HEALTH REVENUE ASSURANCE HOLDINGS, INC.
Entity Central Index Key	0001514443
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2013
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2013
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		46,511,409

XML

Long Term Debt and Notes Payable (Tables)

6 Months Ended

Jun. 30, 2013

Long Term Debt and Notes Payable [Abstract]

Schedule of Long Term debt

	June 30, 2013		December 31, 2012
Bank term loan	$	23,229	$	38,897
Mortgage loan		177,410		180,073
		200,639		218,970
Less current portion		(32,610)		(37,513	)
Total long term portion	$	168,029	$	181,457

Schedule of Notes payable

	June 30, 2013
Principal amount of notes payable	$	1,670,204
Unamortized discount		(808,131	)
Notes payable, net of discount		862,073
Less current portion		(574,718	)
Total Long term portion	$	287,355